Angela Dispenzieri

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1811637/angela-dispenzieri-publications-by-year.pdf
Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,142 papers	57,134 citations	113 h-index	205 g-index
1,197 ext. papers	67,199 ext. citations	5.1 avg, IF	7.55 L-index

#	Paper	IF	Citations
1142	Kidney Transplant Outcomes of Patients With Multiple Myeloma.. *Kidney International Reports*, **2022**, 7, 752-762	4.1	0
1141	A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21	7	4
1140	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. *Leukemia*, **2022**,	10.7	2
1139	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).. *Blood Cancer Journal*, **2022**, 12, 27	7	4
1138	Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution.. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2022**, 1-9	2.7	0
1137	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. *Bone Marrow Transplantation*, **2022**,	4.4	
1136	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. *Blood Cancer Journal*, **2022**, 12, 59	7	0
1135	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.. *Blood Cancer Journal*, **2022**, 12, 67	7	1
1134	Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2022**, 1-9	2.7	0
1133	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. *Leukemia and Lymphoma*, **2022**, 1-6	1.9	0
1132	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.. *JCO Oncology Practice*, **2022**, OP2100789	2.3	
1131	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. *Blood Cancer Journal*, **2022**, 12,	7	0
1130	Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. *Mayo Clinic Proceedings*, **2021**,	6.4	2
1129	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. *Transplantation*, **2021**, 105, 1615-1624	1.8	
1128	Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2021**, 1-6	2.7	1
1127	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNENIS). *Blood*, **2021**, 138, 1333-1333	2.2	
1126	Prognostic Role of IL-6 in POEMS Syndrome. *Blood*, **2021**, 138, 2700-2700	2.2	

1125	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. *Blood*, **2021**, 138, 1617-1617	2.2	
1124	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. *Blood*, **2021**, 138, 2720-2720	2.2	1
1123	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. *Blood*, **2021**, 138, 819-819	2.2	
1122	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. *Blood Cancer Journal*, **2021**, 11, 186	7	1
1121	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. *Blood*, **2021**, 138, 3760-3760	2.2	0
1120	Financial Toxicity and Associated Patient-Reported Quality of Life in Plasma Cell Disorders. *Blood*, **2021**, 138, 4012-4012	2.2	0
1119	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. *Blood*, **2021**, 138, 2721-2721	2.2	1
1118	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma-Pivotal Role of Cytogenetic Changes. *Blood*, **2021**, 138, 3761-3761	2.2	
1117	Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplant (ASCT) for Patients with POEMS Syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes): A CIBMTR Analysis. *Blood*, **2021**, 138, 120-120	2.2	
1116	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. *American Journal of Hematology*, **2021**,	7.1	1
1115	The Role of Non-Coding RNAs in the Pathogenesis of AL Amyloidosis. *Blood*, **2021**, 138, 2659-2659	2.2	
1114	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. *Blood*, **2021**, 138, 3774-3774	2.2	0
1113	Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions. *Blood*, **2021**, 138, 3739-3739	2.2	
1112	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. *Blood*, **2021**, 138, 543-543	2.2	
1111	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. *Blood*, **2021**, 138, 1630-1630	2.2	
1110	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. *Blood*, **2021**, 138, 119-119	2.2	
1109	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. *Blood*, **2021**, 138, 2650-2650	2.2	
1108	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. *Leukemia*, **2021**,	10.7	5

1107	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. *JACC: CardioOncology*, **2021**, 3, 537-546	3.8	3
1106	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. *Leukemia*, **2021**,	10.7	1
1105	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *British Journal of Haematology*, **2021**, 194, 496-507	4.5	12
1104	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. *Mayo Clinic Proceedings*, **2021**, 96, 677-687	6.4	4
1103	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. *Blood Cancer Journal*, **2021**, 11, 50	7	8
1102	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. *Kidney International Reports*, **2021**, 6, 857-864	4.1	0
1101	Clearing drug interferences in myeloma treatment using mass spectrometry. *Clinical Biochemistry*, **2021**, 92, 61-66	3.5	6
1100	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. *Blood Advances*, **2021**, 5, 2101-2105	7.8	5
1099	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. *Orphanet Journal of Rare Diseases*, **2021**, 16, 204	4.2	1
1098	ASSOCIATION BETWEEN CHOROIDAL CHARACTERISTICS AND SYSTEMIC SEVERITY IN AMYLOIDOSIS. *Retina*, **2021**, 41, 1037-1046	3.6	3
1097	MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.. *Journal of Clinical Oncology*, **2021**, 39, 8009-8009	2.2	3
1096	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2021**, 39, e20016-e20016	2.2	
1095	Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience.. *Journal of Clinical Oncology*, **2021**, 39, e20000-e20000	2.2	1
1094	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. *Leukemia*, **2021**, 35, 3604-3607	10.7	4
1093	The Clinical Impact of Proteomics in Amyloid Typing. *Mayo Clinic Proceedings*, **2021**, 96, 1122-1127	6.4	2
1092	Clinical activity of systemic VSV-IFNNIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.. *Journal of Clinical Oncology*, **2021**, 39, 2500-2500	2.2	2
1091	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. *American Journal of Hematology*, **2021**, 96, 945-953	7.1	2
1090	POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2021**, 96, 872-888	7.1	15

1089	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. *Mayo Clinic Proceedings*, **2021**, 96, 1546-1577	6.4	8
1088	A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. *Leukemia*, **2021**,	10.7	8
1087	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. *Blood Cancer Journal*, **2021**, 11, 120	7	3
1086	Belantamab mafodotin detection by MASS-FIX and immunofixation. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, e430-e433	5.9	1
1085	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 451-460.e2	2	2
1084	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. *Transplantation and Cellular Therapy*, **2021**, 27, 589.e1-589.e6		2
1083	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Circulation: Cardiovascular Imaging*, **2021**, 14, e000029	3.9	12
1082	Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study. *Quality of Life Research*, **2021**, 1	3.7	0
1081	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Circulation: Cardiovascular Imaging*, **2021**, 14, e000030	3.9	6
1080	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. *Blood Advances*, **2021**, 5, 2753-2759	7.8	0
1079	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 274-277	4.4	0
1078	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. *Kidney International*, **2021**, 99, 707-715	9.9	5
1077	The novel form of amyloidosis derived from EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) preferentially affects the lower gastrointestinal tract of elderly females. *Histopathology*, **2021**, 78, 459-463	7.3	4
1076	Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. *American Journal of Hematology*, **2021**, 96, E35-E38	7.1	0
1075	Characterization and prognostic implication of delayed complete response in AL amyloidosis. *European Journal of Haematology*, **2021**, 106, 354-361	3.8	3
1074	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. *European Journal of Haematology*, **2021**, 106, 433-436	3.8	0
1073	Autologous stem cell transplantation for multiple myeloma patients aged ≥75 treated with novel agents. *Bone Marrow Transplantation*, **2021**, 56, 1144-1150	4.4	5
1072	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. *British Journal of Haematology*, **2021**, 193, 380-385	4.5	9

1071	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. *Lancet Neurology, The*, **2021**, 20, 49-59	24.1	23
1070	Non-cardiac biopsy sites with high frequency of transthyretin amyloidosis. *ESC Heart Failure*, **2021**, 8, 750-755	3.7	3
1069	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. *American Journal of Hematology*, **2021**, 96, 330-337	7.1	3
1068	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. *Bone Marrow Transplantation*, **2021**, 56, 928-935	4.4	2
1067	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 309.e1-309.e5		
1066	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. *Leukemia and Lymphoma*, **2021**, 62, 316-322	1.9	1
1065	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. *British Journal of Haematology*, **2021**, 192, e28-e31	4.5	2
1064	Systemic amyloidosis from A (AA) to T (ATTR): a review. *Journal of Internal Medicine*, **2021**, 289, 268-292	10.8	35
1063	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. *Leukemia Research Reports*, **2021**, 15, 100242	0.6	0
1062	Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. *Blood Cancer Journal*, **2021**, 11, 29	7	1
1061	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. *Leukemia*, **2021**, 35, 1428-1437	10.7	4
1060	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *American Journal of Hematology*, **2021**, 96, E157-E162	7.1	2
1059	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). *Blood Cancer Journal*, **2021**, 11, 26	7	3
1058	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. *Blood Cancer Journal*, **2021**, 11, 24	7	24
1057	Prognostic restaging after treatment initiation in patients with AL amyloidosis. *Blood Advances*, **2021**, 5, 1029-1036	7.8	3
1056	Coagulation Abnormalities in Light Chain Amyloidosis. *Mayo Clinic Proceedings*, **2021**, 96, 377-387	6.4	3
1055	Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. *International Journal of Cancer*, **2021**, 148, 2807-2814	7.5	4
1054	Reply to: Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. *International Journal of Cancer*, **2021**, 149, 743-744	7.5	0

1053	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Journal of Cardiac Failure*, **2021**,	3.3	1
1052	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. *Leukemia and Lymphoma*, **2021**, 62, 3011-3018	1.9	0
1051	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. *American Journal of Hematology*, **2021**, 96, 1131-1136	7.1	6
1050	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. *Journal of Nuclear Cardiology*, **2021**, 28, 1769-1774	2.1	4
1049	Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. *Mayo Clinic Proceedings*, **2021**, 96, 2768-2778	6.4	6
1048	Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. *JAMA Cardiology*, **2021**, 6, 1267-1274	16.2	10
1047	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. *Clinical Biochemistry*, **2021**, 97, 67-73	3.5	1
1046	The Role of Autologous Stem Cell Transplantation in Amyloidosis. *Oncology*, **2021**, 35, 471-478	1.8	0
1045	Increased Utilization of Virtual Visits and Electronic Approaches in Clinical Research During the COVID-19 Pandemic and Thereafter. *Mayo Clinic Proceedings*, **2021**, 96, 2332-2341	6.4	6
1044	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). *Blood Cancer Journal*, **2021**, 11, 158	7	1
1043	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. *Transplantation and Cellular Therapy*, **2021**, 27, 770.e1-770.e7		0
1042	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS. *JACC: Heart Failure*, **2021**, 9, 736-746	7.9	7
1041	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. *American Journal of Hematology*, **2021**, 96, 446-454	7.1	3
1040	"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. *Blood Cancer Journal*, **2021**, 11, 196	7	3
1039	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. *Blood Advances*, **2020**, 4, 6039-6050	7.8	24
1038	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. *Blood Cancer Journal*, **2020**, 10, 124	7	1
1037	Future Perspectives. *Hematology/Oncology Clinics of North America*, **2020**, 34, 1205-1214	3.1	1
1036	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. *Bone Marrow Transplantation*, **2020**, 55, 2132-2137	4.4	5

1035	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1402-1405	4.7	2
1034	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. *Blood Cancer Journal*, **2020**, 10, 52	7	4
1033	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. *Blood Cancer Journal*, **2020**, 10, 55	7	22
1032	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). *Blood Cancer Journal*, **2020**, 10, 53	7	68
1031	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2020**, 75, 2851-2862	15.1	50
1030	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. *Bone Marrow Transplantation*, **2020**, 55, 1297-1304	4.4	3
1029	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. *Blood Cancer Journal*, **2020**, 10, 39	7	1
1028	CNV Radar: an improved method for somatic copy number alteration characterization in oncology. *BMC Bioinformatics*, **2020**, 21, 98	3.6	4
1027	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. *Bone Marrow Transplantation*, **2020**, 55, 1879-1881	4.4	1
1026	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. *Leukemia and Lymphoma*, **2020**, 61, 1752-1755	1.9	5
1025	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. *American Journal of Hematology*, **2020**, 95, 637-642	7.1	6
1024	N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. *Leukemia*, **2020**, 34, 2749-2753	10.7	17
1023	Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. *JAMA - Journal of the American Medical Association*, **2020**, 324, 79-89	27.4	63
1022	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. *American Journal of Hematology*, **2020**, 95, 1170	7.1	1
1021	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. *Blood Cancer Journal*, **2020**, 10, 20	7	18
1020	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. *British Journal of Haematology*, **2020**, 190, 79-83	4.5	0
1019	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. *Blood Cancer Journal*, **2020**, 10, 4	7	12
1018	The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 111-118	2.7	2

1017	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. *American Journal of Hematology*, **2020**, 95, 497-502	7.1	27
1016	AL patients don't dare go without dara. *Blood*, **2020**, 135, 1509-1510	2.2	2
1015	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. *American Journal of Hematology*, **2020**, 95, E222-E225	7.1	11
1014	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 596-601	2	3
1013	Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. *Leukemia*, **2020**, 34, 3310-3322	10.7	29
1012	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. *Blood*, **2020**, 136, 27-28	2.2	
1011	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. *Blood*, **2020**, 136, 9-10	2.2	
1010	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). *Blood*, **2020**, 136, 40-41	2.2	1
1009	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. *Blood*, **2020**, 136, 44-45	2.2	
1008	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. *Blood*, **2020**, 136, 15-16	2.2	
1007	Financial Toxicity and Impact on Health-Related Quality of Life in Patients with Plasma Cell Disorders. *Blood*, **2020**, 136, 20-21	2.2	1
1006	Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database. *Blood*, **2020**, 136, 4-5	2.2	0
1005	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. *Blood*, **2020**, 136, 14-15	2.2	
1004	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. *Blood*, **2020**, 136, 6-7	2.2	
1003	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. *Blood*, **2020**, 136, 15-16	2.2	
1002	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. *Blood*, **2020**, 136, 21-22	2.2	
1001	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 21-22	2.2	
1000	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. *Blood*, **2020**, 136, 12-13	2.2	

999	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. *Blood*, **2020**, 136, 31-32	2.2	0
998	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. *Blood*, **2020**, 136, 37-38	2.2	
997	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. *Blood*, **2020**, 136, 1-2	2.2	
996	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. *Blood*, **2020**, 136, 41-42	2.2	
995	Waldenstrm Macroglobulinemia in the Very Elderly (75 years):Clinical Characteristics and Outcomes. *Blood*, **2020**, 136, 44-45	2.2	
994	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. *Blood*, **2020**, 136, 52-53	2.2	2
993	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. *Blood*, **2020**, 136, 48-49	2.2	0
992	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. *Blood*, **2020**, 136, 36-37	2.2	3
991	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. *Blood*, **2020**, 136, 44-45	2.2	2
990	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 30-31	2.2	2
989	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2020**, 136, 7-8	2.2	1
988	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). *Blood*, **2020**, 136, 12-13	2.2	2
987	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. *Blood*, **2020**, 136, 22-23	2.2	1
986	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. *Blood Advances*, **2020**, 4, 2236-2244	7.8	7
985	Ixazomib-dexamethasone (Ixa-Dex) vs physicians choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. *Journal of Clinical Oncology*, **2020**, 38, 8546-8546	2.2	5
984	Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. *Clinical Chemistry and Laboratory Medicine*, **2020**, 59, 155-163	5.9	12
983	Prevalence and significance of clonal hematopoiesis of indeterminate prognosis (CHIP) in multiple myeloma.. *Journal of Clinical Oncology*, **2020**, 38, 8542-8542	2.2	0
982	Sporadic late-onset nemaline myopathy with monoclonal paraprotein as a malignancy rather than disimmunity and treatment with chemotherapy-based approach.. *Journal of Clinical Oncology*, **2020**, 38, 8545-8545	2.2	

981	Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation.. *Journal of Clinical Oncology*, **2020**, 38, e20506-e20506	2.2	
980	Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.. *Journal of Clinical Oncology*, **2020**, 38, e20510-e20510	2.2	1
979	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. *Journal of Clinical Oncology*, **2020**, 38, 8516-8516	2.2	
978	Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).. *Journal of Clinical Oncology*, **2020**, 38, e19112-e19112	2.2	1
977	Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis.. *Journal of Clinical Oncology*, **2020**, 38, 8549-8549	2.2	
976	Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. *Journal of Clinical Oncology*, **2020**, 38, e20515-e20515	2.2	
975	Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response.. *Journal of Clinical Oncology*, **2020**, 38, e20520-e20520	2.2	
974	New developments in diagnosis, risk assessment and management in systemic amyloidosis. *Blood Reviews*, **2020**, 40, 100636	11.1	21
973	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. *British Journal of Haematology*, **2020**, 188, 394-403	4.5	23
972	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. *American Journal of Hematology*, **2020**, 95, E8-E10	7.1	5
971	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. *American Journal of Hematology*, **2020**, 95, 4-9	7.1	6
970	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 53-56	2	5
969	Multiple Myeloma and Related Disorders **2020**, 1884-1910.e7		2
968	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. *American Journal of Hematology*, **2020**, 95, 310-315	7.1	16
967	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. *American Journal of Hematology*, **2020**, 95, E60-E62	7.1	1
966	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. *American Journal of Hematology*, **2020**, 95, 274-281	7.1	18
965	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. *Leukemia*, **2020**, 34, 1373-1382	10.7	22
964	Revisiting complete response in light chain amyloidosis. *Leukemia*, **2020**, 34, 1472-1475	10.7	10

963	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. *Leukemia*, **2020**, 34, 1135-1143	10.7	19
962	The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. *Orphanet Journal of Rare Diseases*, **2020**, 15, 268	4.2	4
961	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. *Cancer Medicine*, **2020**, 9, 8895-8901	4.8	1
960	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 6581-6588	12.9	9
959	Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. *Cancer Medicine*, **2020**, 9, 8923-8930	4.8	1
958	Predictors of short-term survival in Waldenström Macroglobulinemia. *Leukemia and Lymphoma*, **2020**, 61, 2975-2979	1.9	1
957	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. *American Journal of Hematology*, **2020**, 95, 1280-1287	7.1	10
956	A Proteomic Atlas of Cardiac Amyloid Plaques. *JACC: CardioOncology*, **2020**, 2, 632-643	3.8	11
955	Monoclonal gammopathies of clinical significance. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 380-388	3.1	9
954	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Advances*, **2020**, 4, 3509-3519	7.8	27
953	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer Journal*, **2020**, 10, 82	7	17
952	Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. *Mayo Clinic Proceedings*, **2020**, 95, 1852-1864	6.4	39
951	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 87	7	7
950	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. *American Journal of Hematology*, **2020**, 95, 1553-1561	7.1	9
949	Free Light Chain Assay Drift: Potential for Misdiagnosis?. *journal of applied laboratory medicine, The*, **2020**, 5, 1411-1413	2	2
948	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 13-16	2.7	21
947	MYC dysregulation in the progression of multiple myeloma. *Leukemia*, **2020**, 34, 322-326	10.7	56
946	Overview of Castleman disease. *Blood*, **2020**, 135, 1353-1364	2.2	71

945	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. *Blood Advances*, **2020**, 4, 322-326	7.8	4
944	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. *Blood Cancer Journal*, **2020**, 10, 41	7	16
943	Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. *Blood Cancer Journal*, **2019**, 9, 72	7	21
942	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Journal of Cardiac Failure*, **2019**, 25, 854-865	3.3	40
941	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Journal of Cardiac Failure*, **2019**, 25, e1-e39	3.3	56
940	Comparative analysis of staging systems in AL amyloidosis. *Leukemia*, **2019**, 33, 811-814	10.7	15
939	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. *American Journal of Hematology*, **2019**, 94, E117-E120	7.1	6
938	Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis. *Journal of the American College of Cardiology*, **2019**, 73, 589-597	15.1	62
937	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. *Mayo Clinic Proceedings*, **2019**, 94, 1834-1839	6.4	4
936	Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry. *Clinical Chemistry*, **2019**, 65, 1015-1022	5.5	18
935	Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis. *Journal of Clinical Medicine*, **2019**, 8,	5.1	6
934	Reply: Cardiac Amyloidosis, Atrial Arrhythmias, Thrombus, and Stroke: A Vexing Problem. *Journal of the American College of Cardiology*, **2019**, 73, 2911-2913	15.1	0
933	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. *Blood Cancer Journal*, **2019**, 9, 49	7	4
932	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. *Leukemia and Lymphoma*, **2019**, 60, 2960-2967	1.9	2
931	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1520-1525	4.7	6
930	POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2019**, 94, 812-827	7.1	92
929	Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin. *Journal of Clinical Oncology*, **2019**, 37, 171-173	2.2	18
928	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. *British Journal of Haematology*, **2019**, 185, 701-707	4.5	10

927	Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32	7	22
926	Two types of amyloidosis presenting in a single patient: a case series. *Blood Cancer Journal*, **2019**, 9, 30	7	29
925	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. *Bone Marrow Transplantation*, **2019**, 54, 1775-1779	4.4	5
924	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. *American Journal of Hematology*, **2019**, 94, 751-756	7.1	6
923	Heavy Chain Fibrillary Glomerulonephritis: A Case Report. *American Journal of Kidney Diseases*, **2019** , 74, 276-280	7.4	11
922	Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure. *Mayo Clinic Proceedings*, **2019**, 94, 447-454	6.4	2
921	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. *Mayo Clinic Proceedings*, **2019**, 94, 465-471	6.4	47
920	Substratification of patients with newly diagnosed standard-risk multiple myeloma. *British Journal of Haematology*, **2019**, 185, 254-260	4.5	8
919	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. *Leukemia*, **2019**, 33, 1268-1272	10.7	4
918	Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. *Leukemia*, **2019**, 33, 254-257	10.7	40
917	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. *Bone Marrow Transplantation*, **2019**, 54, 442-447	4.4	5
916	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone Marrow Transplantation*, **2019**, 54, 353-367	4.4	51
915	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. *British Journal of Haematology*, **2019**, 187, 588-594	4.5	26
914	The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry. *Kidney International*, **2019**, 96, 1005-1009	9.9	16
913	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 101-102	2.7	4
912	Transthyretin amyloidosis in patients with undifferentiated heart failure. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 33-34	2.7	0
911	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. *Blood Advances*, **2019**, 3, 1226-1229	7.8	3
910	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. *Cancer*, **2019**, 125, 3574-3581	6.4	3

909	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. *American Journal of Hematology*, **2019**, 94, 1020-1026	7.1	25
908	Monoclonal gammopathy-associated thrombotic microangiopathy. *American Journal of Hematology* , **2019**, 94, E250-E253	7.1	17
907	Myocardial Stiffness by Intrinsic Cardiac Elastography in Patients with Amyloidosis: Comparison with Chamber Stiffness and Global Longitudinal Strain. *Journal of the American Society of Echocardiography*, **2019**, 32, 958-968.e4	5.8	11
906	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. *American Journal of Hematology*, **2019**, 94, 1066-1071	7.1	9
905	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. *Blood*, **2019**, 134, 3510-3510	2.2	1
904	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. *Blood*, **2019**, 134, 794-794	2.2	8
903	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). *Blood*, **2019**, 134, 139-139	2.2	29
902	A Proteomic Atlas of Cardiac Amyloidosis. *Blood*, **2019**, 134, 1790-1790	2.2	1
901	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. *Blood*, **2019**, 134, 72-72	2.2	1
900	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. *Blood*, **2019**, 134, 4334-4334	2.2	1
899	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. *Blood*, **2019**, 134, 1846-1846	2.2	2
898	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. *Blood*, **2019**, 134, 4386-4386	2.2	2
897	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 864-864	2.2	12
896	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. *Blood*, **2019**, 134, 1905-1905	2.2	1
895	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.. *Journal of Clinical Oncology*, **2019**, 37, 7559-7559	2.2	6
894	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. *Mayo Clinic Proceedings*, **2019**, 94, 455-464	6.4	13
893	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. *Blood*, **2019**, 134, 4505-4505	2.2	
892	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). *Blood*, **2019**, 134, 5523-5523	2.2	

891	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. *Blood*, **2019**, 134, 1532-1532	2.2	
890	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 4396-4396	2.2	
889	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. *Blood*, **2019**, 134, 3080-3080	2.2	
888	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 5833-5833	2.2	
887	The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias. *Blood*, **2019**, 134, 4362-4362	2.2	
886	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. *Blood*, **2019**, 134, 1770-1770	2.2	
885	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. *Blood*, **2019**, 134, 5532-5532	2.2	
884	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. *Blood*, **2019**, 134, 3171-3171	2.2	0
883	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. *Blood*, **2019**, 134, 1800-1800	2.2	1
882	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 2197-2197	2.2	
881	The Transcriptome of Immunomodulator-Resistant Multiple Myeloma. *Blood*, **2019**, 134, 1772-1772	2.2	
880	Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma. *Blood*, **2019**, 134, 3061-3061	2.2	
879	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. *Blood*, **2019**, 134, 2013-2013	2.2	
878	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. *Blood*, **2019**, 134, 5490-5490	2.2	1
877	Classification of Plasma Cell Disorders by 21 Tesla Fourier Transform Ion Cyclotron Resonance Top-Down and Middle-Down MS/MS Analysis of Monoclonal Immunoglobulin Light Chains in Human Serum. *Analytical Chemistry*, **2019**, 91, 3263-3269	7.8	13
876	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. *American Journal of Hematology*, **2019**, 94, E141-E143	7.1	13
875	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. *Leukemia*, **2019**, 33, 1273-1277	10.7	7
874	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. *Mayo Clinic Proceedings*, **2019**, 94, 472-483	6.4	33

873	Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938	7.8	20
872	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. *Blood Advances*, **2019**, 3, 744-750	7.8	15
871	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. *Blood Cancer Journal*, **2019**, 9, 102	7	27
870	P336A descriptive analysis of patients with wild-type ATTR cardiomyopathy from the transthyretin amyloidosis outcomes survey. *European Heart Journal*, **2019**, 40,	9.5	2
869	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430	7.1	5
868	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. *Biology of Blood and Marrow Transplantation*, **2019**, 25, e108-e111	4.7	11
867	Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. *Blood*, **2019**, 133, 763-766	2.2	20
866	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. *Bone Marrow Transplantation*, **2019**, 54, 1077-1081	4.4	3
865	Increased Myocardial Stiffness Detected by Intrinsic Cardiac Elastography in Patients With Amyloidosis: Impact on Outcomes. *JACC: Cardiovascular Imaging*, **2019**, 12, 375-377	8.4	9
864	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. *Circulation*, **2019**, 139, 431-443	16.7	180
863	Primary systemic amyloidosis in patients with Waldenstrm macroglobulinemia. *Leukemia*, **2019**, 33, 790-794	10.7	16
862	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. *Leukemia*, **2019**, 33, 730-738	10.7	11
861	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nature Reviews Nephrology*, **2019**, 15, 45-59	14.9	189
860	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. *Leukemia*, **2019**, 33, 527-531	10.7	30
859	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. *Leukemia*, **2019**, 33, 531-536	10.7	60
858	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. *American Journal of Hematology*, **2019**, 94, 306-311	7.1	9
857	Opening a can of worms in AL progression. *Blood*, **2018**, 131, 475-476	2.2	1
856	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. *Leukemia*, **2018**, 32, 1421-1426	10.7	5

855	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. *Leukemia*, **2018**, 32, 2240-2249	10.7	49
854	Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis. *Transplantation*, **2018**, 102, 1909-1913	1.8	12
853	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. *Haematologica*, **2018**, 103, 1229-1234	6.6	8
852	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. *Mayo Clinic Proceedings*, **2018**, 93, 739-746	6.4	16
851	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. *American Journal of Hematology*, **2018**, 93, 889-894	7.1	8
850	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2127-2132	4.7	12
849	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. *Annals of Hematology*, **2018**, 97, 1417-1425	3	43
848	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
847	POEMS Syndrome. *Hematologic Malignancies*, **2018**, 177-189	0	1
846	The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. *Leukemia*, **2018**, 32, 1243-1246	10.7	12
845	Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. *Haematologica*, **2018**, 103, e135-e137	6.6	46
844	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. *New England Journal of Medicine*, **2018**, 378, 241-249	59.2	216
843	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. *Bone Marrow Transplantation*, **2018**, 53, 326-333	4.4	4
842	Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. *Leukemia*, **2018**, 32, 986-995	10.7	41
841	Aortic valve replacement in patients with amyloidosis. *Journal of Thoracic and Cardiovascular Surgery*, **2018**, 156, 98-103	1.5	8
840	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. *Mayo Clinic Proceedings*, **2018**, 93, 56-58	6.4	12
839	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. *British Journal of Haematology*, **2018**, 182, 71-77	4.5	9
838	POEMS Syndrome **2018**, 609-616		

837	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2018**, 25, 86-92	2.7	40
836	Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. *Muscle and Nerve*, **2018**, 57, E8-E13	3.4	5
835	Natural history of t(11;14) multiple myeloma. *Leukemia*, **2018**, 32, 131-138	10.7	43
834	DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 51-56	12.7	62
833	OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS. *Retina*, **2018**, 38, 1371-1376	3.6	27
832	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2018**, 93, 179-186	7.1	29
831	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 187-194	7.1	45
830	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). *American Journal of Hematology*, **2018**, 93, 17-22	7.1	9
829	Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. *Leukemia*, **2018**, 32, 719-728	10.7	12
828	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. *Leukemia*, **2018**, 32, 712-718	10.7	20
827	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. *Leukemia*, **2018**, 32, 729-735	10.7	36
826	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2157-2159	4.7	3
825	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 70	7	11
824	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. *Blood Cancer Journal*, **2018**, 8, 67	7	36
823	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. *Blood*, **2018**, 132, 1478-1485	2.2	93
822	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. *American Journal of Hematology*, **2018**, 93, 1207-1210	7.1	1
821	MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2018**, 25, 101-108	2.7	8
820	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circulation: Cardiovascular Imaging*, **2018**, 11, e006588	3.9	31

819	Immunoglobulin Light Chain Amyloidosis (AL) **2018**, 651-672		1
818	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 1384-1393	7.1	15
817	Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. *Current Cancer Drug Targets*, **2018**, 18, 177-187	2.8	73
816	MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. *American Journal of Hematology*, **2018**, 93, E368-E370	7.1	26
815	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e493-e499	2	17
814	Cardiac amyloidosis in aortic stenosis-icebergs and Archimedes' principle. *Journal of Thoracic and Cardiovascular Surgery*, **2018**, 156, 966-967	1.5	
813	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 1037-1046	6.9	32
812	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer Journal*, **2018**, 8, 59	7	115
811	A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. *Blood*, **2018**, 132, 670-672	2.2	33
810	Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. *Blood*, **2018**, 132, 1879-1879	2.2	1
809	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 304-304	2.2	8
808	Longer Term Follow up of the Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT). *Blood*, **2018**, 132, 1992-1992	2.2	4
807	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. *Blood*, **2018**, 132, 4460-4460	2.2	0
806	Long-Term Survivorship with Active Multiple Myeloma. *Blood*, **2018**, 132, 1912-1912	2.2	
805	Comparative Analysis of Staging Systems in AL Amyloidosis. *Blood*, **2018**, 132, 3228-3228	2.2	
804	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 622-622	2.2	
803	Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry. *Blood*, **2018**, 132, 4458-4458	2.2	
802	Depth of Response in Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 4141-4141	2.2	0

801	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3159-3159	2.2	
800	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3158-3158	2.2	
799	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449	2.2	
798	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. *Blood*, **2018**, 132, 2147-2147	2.2	
797	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. *Blood*, **2018**, 132, 3226-3226	2.2	
796	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. *Blood*, **2018**, 132, 1606-1606	2.2	1
795	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. *Blood*, **2018**, 132, 4613-4613	2.2	
794	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. *Blood*, **2018**, 132, 4497-4497	2.2	
793	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). *Blood*, **2018**, 132, 4502-4502	2.2	
792	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 1902-1902	2.2	
791	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. *Blood*, **2018**, 132, 5594-5594	2.2	
790	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. *Blood*, **2018**, 132, 3227-3227	2.2	
789	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. *Blood*, **2018**, 132, 5610-5610	2.2	
788	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2018**, 132, 3268-3268	2.2	
787	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. *Blood*, **2018**, 132, 3436-3436	2.2	
786	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 2884-2884	2.2	1
785	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2018**, 132, 4615-4615	2.2	
784	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. *Blood*, **2018**, 132, 3160-3160	2.2	2

783	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. *Blood*, **2018**, 132, 4152-4152	2.2	1
782	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. *Blood*, **2018**, 132, 719-719	2.2	
781	POEMS Syndrome: Diagnosis and Investigative Work-up. *Hematology/Oncology Clinics of North America*, **2018**, 32, 119-139	3.1	22
780	Skull base plasmacytoma: A unique case of POEMS syndrome with a plasmacytoma causing craniocervical instability. *Journal of Clinical Neuroscience*, **2018**, 47, 254-257	2.2	0
779	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. *Blood*, **2018**, 131, 301-310	2.2	151
778	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. *Bone Marrow Transplantation*, **2018**, 53, 155-161	4.4	3
777	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. *Journal of Clinical Oncology*, **2018**, 36, 1323-1329	2.2	68
776	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 106	7	13
775	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 116	7	38
774	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. *Blood Cancer Journal*, **2018**, 8, 125	7	17
773	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. *Blood Cancer Journal*, **2018**, 8, 96	7	29
772	Systemic immunoglobulin light chain amyloidosis. *Nature Reviews Disease Primers*, **2018**, 4, 38	51.1	207
771	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. *Blood*, **2018**, 132, 2115-2124	2.2	127
770	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2018**, 93, 1518-1523	7.1	15
769	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. *Blood Advances*, **2018**, 2, 769-776	7.8	16
768	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. *Blood Advances*, **2018**, 2, 3149-3154	7.8	17
767	A predictive model for risk of early grade – infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. *Leukemia*, **2018**, 32, 1404-1413	10.7	28
766	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2360-2364	4.7	13

765	Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 439-445	12.7	50
764	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Leukemia*, **2017**, 31, 92-99	10.7	29
763	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. *Leukemia and Lymphoma*, **2017**, 58, 308-315	1.9	12
762	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. *Blood*, **2017**, 129, 1646-1657	2.2	234
761	Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 431-438	12.7	20
760	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 598-605	4.7	32
759	Ixazomib-induced thrombotic microangiopathy. *American Journal of Hematology*, **2017**, 92, E53-E55	7.1	18
758	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. *Annals of Medicine*, **2017**, 49, 545-551	1.5	27
757	Cardiac MR elastography for quantitative assessment of elevated myocardial stiffness in cardiac amyloidosis. *Journal of Magnetic Resonance Imaging*, **2017**, 46, 1361-1367	5.6	44
756	Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases. *European Respiratory Journal*, **2017**, 49,	13.6	23
755	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e528	7	23
754	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. *American Journal of Hematology*, **2017**, 92, 435-440	7.1	10
753	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. *Blood*, **2017**, 129, 82-87	2.2	41
752	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. *Blood*, **2017**, 129, 2111-2119	2.2	181
751	Apolipoprotein A-IV-Associated Cardiac Amyloidosis. *Journal of the American College of Cardiology*, **2017**, 69, 2248-2249	15.1	14
750	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. *Bone Marrow Transplantation*, **2017**, 52, 1126-1132	4.4	20
749	The yin and yang of autophagy in AL amyloidosis. *Blood*, **2017**, 129, 2044-2045	2.2	3
748	The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. *American Journal of Hematology*, **2017**, 92, 772-779	7.1	71

747	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 40-41	2.7	3
746	Feasibility study of cardiac magnetic resonance elastography in cardiac amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 161	2.7	3
745	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 44-45	2.7	1
744	Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2017**, 24, 165-166	2.7	3
743	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. *Journal of Internal Medicine*, **2017**, 281, 611-619	10.8	10
742	Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. *Leukemia*, **2017**, 31, 2791-2798	10.7	92
741	Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. *Heart*, **2017**, 103, 1065-1072	5.1	89
740	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. *Leukemia*, **2017**, 31, 1562-1569	10.7	70
739	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e569	7	6
738	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. *Blood*, **2017**, 130, 597-605	2.2	89
737	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. *American Journal of Hematology*, **2017**, 92, E507-E512	7.1	3
736	IgM myeloma: A multicenter retrospective study of 134 patients. *American Journal of Hematology*, **2017**, 92, 746-751	7.1	21
735	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. *American Journal of Hematology*, **2017**, 92, 668-673	7.1	46
734	Validation of a prognostic score for patients with POEMS syndrome: a mayo clinic cohort. *Leukemia*, **2017**, 31, 1251	10.7	6
733	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clinic Proceedings*, **2017**, 92, 578-598	6.4	88
732	Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept. *American Journal of Hematology*, **2017**, 92, 536-541	7.1	13
731	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. *American Journal of Hematology*, **2017**, 92, 549-554	7.1	18
730	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet, The*, **2017**, 389, 519-527	40	496

729	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. *Blood*, **2017**, 129, 299-306	2.2	61
728	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265	13.4	82
727	Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. *Progress in Transplantation*, **2017**, 27, 246-250	1.1	14
726	Safety, pharmacokinetics, metabolism and radiation dosimetry of F-tetrafluoroborate (F-TFB) in healthy human subjects. *EJNMMI Research*, **2017**, 7, 90	3.6	14
725	Myeloma in Elderly Patients: When Less Is More and More Is More. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 575-585	7.1	10
724	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. *Mayo Clinic Proceedings*, **2017**, 92, 908-917	6.4	43
723	First report of MYD88 somatic mutation in IgM-associated light chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 42-43	2.7	7
722	Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. *Blood*, **2017**, 130, 1578-1584	2.2	15
721	Attitudes about when and how to treat patients with AL amyloidosis: an international survey. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 213-216	2.7	24
720	Ocular Manifestations of Familial Transthyretin Amyloidosis. *American Journal of Ophthalmology*, **2017**, 183, 156-162	4.9	40
719	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e600	7	43
718	A phase 1 trial of Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. *Bone Marrow Transplantation*, **2017**, 52, 1372-1377	4.4	10
717	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. *British Journal of Haematology*, **2017**, 178, 888-895	4.5	14
716	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. *Haematologica*, **2017**, 102, 1439-1445	6.6	19
715	POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management. *American Journal of Hematology*, **2017**, 92, 814-829	7.1	108
714	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. *British Journal of Haematology*, **2017**, 179, 98-105	4.5	12
713	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. *American Journal of Hematology*, **2017**, 92, 1146-1155	7.1	22
712	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 183-188	2.7	1

711	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. *Blood*, **2017**, 130, 1198-1204	2.2	46
710	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. *Bone Marrow Transplantation*, **2017**, 52, 34-40	4.4	20
709	Natural history of amyloidosis isolated to fat and bone marrow aspirate. *British Journal of Haematology*, **2017**, 179, 170-172	4.5	7
708	IgM Amyloidosis **2017**, 195-207		
707	MRI of pathology-proven peripheral nerve amyloidosis. *Skeletal Radiology*, **2017**, 46, 65-73	2.7	8
706	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. *American Journal of Hematology*, **2017**, 92, 50-55	7.1	30
705	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. *Leukemia*, **2017**, 31, 130-135	10.7	46
704	POEMS Syndrome and Castleman Disease **2017**, 41-69		2
703	Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. *JACC: Cardiovascular Imaging*, **2017**, 10, 398-407	8.4	56
702	Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. *Blood Cancer Journal*, **2017**, 7, e618	7	43
701	High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e590	7	50
700	Myeloma in Elderly Patients: When Less Is More and More Is More. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 575-585	7.1	18
699	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. *Leukemia*, **2016**, 30, 633-9	10.7	42
698	Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. *Leukemia*, **2016**, 30, 995-8	10.7	10
697	Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. *Journal of the American College of Cardiology*, **2016**, 68, 1014-20	15.1	269
696	Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. *JAMA Cardiology*, **2016**, 1, 880-889	16.2	200
695	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 1129-1134	7.1	42
694	Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. *Clinical Chemistry*, **2016**, 62, 1345-52	5.5	31

693	First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. *Blood*, **2016**, 127, 2936-8	2.2	16
692	Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis. *Journal of Cardiovascular Electrophysiology*, **2016**, 27, 1167-1173	2.7	46
691	HLA polymorphism and risk of multiple myeloma. *Leukemia*, **2016**, 30, 2260-2264	10.7	16
690	IAP antagonists induce anti-tumor immunity in multiple myeloma. *Nature Medicine*, **2016**, 22, 1411-1420	50.5	99
689	Effect of Systemic Therapies on Outcomes following Vertebroplasty among Patients with Multiple Myeloma. *American Journal of Neuroradiology*, **2016**, 37, 2400-2406	4.4	5
688	Clinical spectrum of Castleman disease-associated neuropathy. *Neurology*, **2016**, 87, 2457-2462	6.5	25
687	Clinical characteristics and outcomes in biclonal gammopathies. *American Journal of Hematology*, **2016**, 91, 473-5	7.1	20
686	Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. *Histopathology*, **2016**, 68, 648-56	7.3	32
685	Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. *Acta Haematologica*, **2016**, 135, 172-90	2.7	47
684	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. *Leukemia*, **2016**, 30, 1079-85	10.7	24
683	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. *Blood Cancer Journal*, **2016**, 6, e401	7	21
682	Monitoring free light chains in serum using mass spectrometry. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1073-83	5.9	24
681	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. *Nephrology Dialysis Transplantation*, **2016**, 31, 1284-9	4.3	21
680	Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration. *Clinical Chemistry*, **2016**, 62, 243-51	5.5	41
679	Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 796-801	4.7	12
678	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. *Blood*, **2016**, 128, 2082-2082	2.2	1
677	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). *Blood*, **2016**, 128, 2968-2968	2.2	3
676	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. *Blood*, **2016**, 128, 2972-2972	2.2	2

675	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. *Blood*, **2016**, 128, 3272-3272	2.2	1
674	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. *Blood*, **2016**, 128, 3317-3317	2.2	3
673	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. *Blood*, **2016**, 128, 3337-3337	2.2	5
672	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. *Blood*, **2016**, 128, 3444-3444	2.2	1
671	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. *Blood*, **2016**, 128, 4627-4627	2.2	1
670	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. *World Journal of Transplantation*, **2016**, 6, 380-8	2.3	44
669	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2016**, 128, 5615-5615	2.2	
668	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. *Blood*, **2016**, 128, 996-996	2.2	
667	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. *Blood*, **2016**, 128, 3273-3273	2.2	
666	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. *Blood*, **2016**, 128, 3251-3251	2.2	
665	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. *Blood*, **2016**, 128, 1810-1810	2.2	
664	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. *Blood*, **2016**, 128, 3306-3306	2.2	
663	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. *Blood*, **2016**, 128, 3269-3269	2.2	
662	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. *Blood*, **2016**, 128, 3338-3338	2.2	
661	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. *Blood*, **2016**, 128, 3255-3255	2.2	
660	Outcome of Very Young (≤40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. *Blood*, **2016**, 128, 5576-5576	2.2	
659	Urinary Exosomes Detect Amyloidogenic Light Chain in Patients Who Have Renal Progression Despite a Hematologic Complete Response. *Blood*, **2016**, 128, 3268-3268	2.2	
658	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. *Blood*, **2016**, 128, 2187-2187	2.2	

657	Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. *Clinical Chemistry*, **2016**, 62, 1334-44	5.5	93
656	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). *Journal of the American College of Cardiology*, **2016**, 68, 161-72	15.1	215
655	18F-Florbetapir and 18F-FDG PET/CT in Systemic Immunoglobulin Light Chain Amyloidosis Involving the Peripheral Nerves. *Clinical Nuclear Medicine*, **2016**, 41, e115-7	1.7	10
654	Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. *Blood Coagulation and Fibrinolysis*, **2016**, 27, 101-8	1	5
653	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. *Cancer*, **2016**, 122, 2197-205	6.4	28
652	Autologous stem cell transplant for multiple myeloma patients 70 years or older. *Bone Marrow Transplantation*, **2016**, 51, 1449-1455	4.4	37
651	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. *American Journal of Hematology*, **2016**, 91, 984-8	7.1	37
650	Nerve pathologic features differentiate POEMS syndrome from CIDP. *Acta Neuropathologica Communications*, **2016**, 4, 116	7.3	33
649	Prevalence, incidence and survival of smoldering multiple myeloma in the United States. *Blood Cancer Journal*, **2016**, 6, e486	7	34
648	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. *Blood*, **2016**, 128, 2415-2422	2.2	42
647	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. *Blood Cancer Journal*, **2016**, 6, e454	7	42
646	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. *Blood Cancer Journal*, **2016**, 6, e512	7	28
645	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. *Haematologica*, **2016**, 101, 1102-9	6.6	9
644	Myeloma: management of the newly diagnosed high-risk patient. *Hematology American Society of Hematology Education Program*, **2016**, 2016, 485-494	3.1	15
643	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. *Leukemia Research*, **2016**, 44, 32-9	2.7	13
642	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 447-52	2	19
641	LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis. *JACC: Cardiovascular Imaging*, **2016**, 9, 680-6	8.4	50
640	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. *Leukemia*, **2016**, 30, 2208-2213	10.7	55

639	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. *Bone Marrow Transplantation*, **2016**, 51, 1156-8	4.4	14
638	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*, **2016**, 133, 2404-12	16.7	792
637	Abnormal stress echocardiography findings in cardiac amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2016**, 23, 124-31	2.7	4
636	Myelomatous Involvement of the Central Nervous System. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 644-654	2	29
635	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. *Mayo Clinic Proceedings*, **2016**, 91, 1354-1361	6.4	30
634	Immunoglobulin Light Chain Systemic Amyloidosis. *Cancer Treatment and Research*, **2016**, 169, 273-318	3.5	17
633	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. *Leukemia*, **2016**, 30, 1979-1986	10.7	52
632	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. *American Journal of Hematology*, **2016**, 91, 1123-1128	7.1	52
631	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. *American Journal of Hematology*, **2016**, 91, 585-9	7.1	40
630	Natural history and therapy of AL cardiac amyloidosis. *Heart Failure Reviews*, **2015**, 20, 155-62	5	70
629	Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. *European Journal of Haematology*, **2015**,	3.8	4
628	Clinical course and prognosis of non-secretory multiple myeloma. *European Journal of Haematology* , **2015**, 95, 57-64	3.8	33
627	Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. *Mayo Clinic Proceedings*, **2015**, 90, 587-96	6.4	70
626	Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. *Mayo Clinic Proceedings*, **2015**, 90, 1054-81	6.4	81
625	Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2015**, 22, 123-31	2.7	59
624	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. *Leukemia and Lymphoma*, **2015**, 56, 1723-6	1.9	14
623	Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. *Patient*, **2015**, 8, 207-16	3.7	15
622	Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 349-357.e2	2	8

621	Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. *Neurology*, **2015**, 84, 1981-7	6.5	50
620	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. *Leukemia*, **2015**, 29, 2033-8	10.7	22
619	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2015**, 50, 1513-8	4.4	30
618	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. *Blood Cancer Journal*, **2015**, 5, e310	7	51
617	Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. *Blood Cancer Journal*, **2015**, 5, e294	7	4
616	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. *American Journal of Hematology*, **2015**, 90, 524-8	7.1	25
615	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. *Blood Cancer Journal*, **2015**, 5, e338	7	62
614	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. *Journal of Clinical Oncology*, **2015**, 33, 3741-9	2.2	130
613	Computed tomography assessment of bone lesions in patients with POEMS syndrome. *European Radiology*, **2015**, 25, 497-504	8	23
612	Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 335-41	4.7	50
611	Multiple myeloma after kidney transplantation. *Clinical Transplantation*, **2015**, 29, 76-84	3.8	12
610	Pathophysiology and treatment of cardiac amyloidosis. *Nature Reviews Cardiology*, **2015**, 12, 91-102	14.8	85
609	Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis. *Clinical Genetics*, **2015**, 88, 396-400	4	20
608	Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. *British Journal of Haematology*, **2015**, 168, 82-93	4.5	9
607	Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy. *Muscle and Nerve*, **2015**, 52, 658-9	3.4	24
606	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. *American Journal of Hematology*, **2015**, 90, 888-91	7.1	14
605	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. *American Journal of Hematology*, **2015**, 90, 981-5	7.1	28
604	POEMS syndrome: update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2015**, 90, 951-62	7.1	86

603	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. *Blood Cancer Journal*, **2015**, 5, e296	7	73
602	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. *Leukemia and Lymphoma*, **2015**, 56, 3357-64	1.9	28
601	Blaming the Right Fluorescent in Situ Hybridization. *Journal of Clinical Oncology*, **2015**, 33, 3976	2.2	4
600	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. *Blood Cancer Journal*, **2015**, 5, e364	7	70
599	Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. *Blood Cancer Journal*, **2015**, 5, e363	7	26
598	Pulmonary morbidity improves after autologous stem cell transplantation in POEMS syndrome. *Respiratory Medicine*, **2015**, 109, 122-30	4.6	9
597	New cancers after autotransplantations for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 738-45	4.7	28
596	Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis. *Journal of Rheumatology*, **2015**, 42, 181-7	4.1	17
595	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. *American Journal of Hematology*, **2015**, 90, 181-6	7.1	60
594	Diagnosis of monoclonal gammopathy of renal significance. *Kidney International*, **2015**, 87, 698-711	9.9	261
593	Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. *Clinical Chemistry*, **2015**, 61, 360-7	5.5	47
592	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). *Blood*, **2015**, 126, 1774-1774	2.2	5
591	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. *Blood*, **2015**, 126, 1830-1830	2.2	1
590	Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777. *Blood*, **2015**,	2.2	39
589	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. *Blood*, **2015**, 126, 3050-3050	2.2	8
588	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. *Blood*, **2015**, 126, 3177-3177	2.2	3
587	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. *Blood*, **2015**, 126, 4197-4197	2.2	5
586	Thrombotic Microangiopathy in Multiple Myeloma. *Blood*, **2015**, 126, 5317-5317	2.2	2

585	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). *Blood*, **2015**, 126, 3292-3292	2.2	
584	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. *Blood*, **2015**, 126, 3039-3039	2.2	
583	AL Amyloidosis and Patient Reported Quality of Life. *Blood*, **2015**, 126, 3317-3317	2.2	
582	A Rapid MALDI-TOF Method for Isotyping and Quantitating M-Proteins in a Single Assay: Longitudinal Comparison to Serum Protein Electrophoresis and Hevylite for Monitoring Patients with Monoclonal Gammopathies. *Blood*, **2015**, 126, 1780-1780	2.2	
581	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 4176-4176	2.2	
580	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. *Blood*, **2015**, 126, 5303-5303	2.2	
579	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. *Blood*, **2015**, 126, 3044-3044	2.2	
578	Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. *British Journal of Haematology*, **2014**, 165, 39-48	4.5	34
577	POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2014**, 89, 214-23	7.1	106
576	Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. *American Journal of Cardiology*, **2014**, 113, 1723-7	3	83
575	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. *Leukemia*, **2014**, 28, 1122-8	10.7	880
574	Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. *Leukemia*, **2014**, 28, 455-7	10.7	4
573	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. *European Journal of Haematology*, **2014**, 92, 485-90	3.8	21
572	Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry. *Journal of Proteome Research*, **2014**, 13, 5198-205	5.6	26
571	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. *Lancet Haematology,the*, **2014**, 1, e28-e36	14.6	31
570	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology, The*, **2014**, 15, e538-48	21.7	2253
569	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. *British Journal of Haematology*, **2014**, 167, 500-5	4.5	62
568	Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS. *Journal of Proteome Research*, **2014**, 13, 1905-10	5.6	42

567	Older patients with myeloma derive similar benefit from autologous transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1796-803	4.7	66
566	Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. *Journal of Proteome Research*, **2014**, 13, 1419-27	5.6	87
565	Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. *Leukemia*, **2014**, 28, 398-403	10.7	45
564	Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *New England Journal of Medicine*, **2014**, 371, 906-17	59.2	565
563	Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 222-8	4.7	29
562	Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy. *Journal of the American Society of Echocardiography*, **2014**, 27, 440-7	5.8	25
561	Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. *JACC: Heart Failure*, **2014**, 2, 113-22	7.9	212
560	Remission of disseminated cancer after systemic oncolytic virotherapy. *Mayo Clinic Proceedings*, **2014**, 89, 926-33	6.4	202
559	Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 402-408.e1	4.7	79
558	Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. *Blood*, **2014**, 123, 1479-82	2.2	53
557	Renal risk and response in amyloidosis. *Blood*, **2014**, 124, 2315-6	2.2	6
556	S0120 G.E.M.S.: genomics encounters MGUS and SMM. *Blood*, **2014**, 123, 4-5	2.2	2
555	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. *Blood*, **2014**, 124, 907-12	2.2	83
554	Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. *Haematologica*, **2014**, 99, 1239-47	6.6	110
553	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. *Bone Marrow Transplantation*, **2014** , 49, 201-5	4.4	19
552	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. *Leukemia*, **2014**, 28, 2060-5	10.7	83
551	Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. *Leukemia*, **2014**, 28, 1537-42	10.7	91
550	Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. *Bone Marrow Transplantation*, **2014**, 49, 416-21	4.4	46

549	IMWG consensus on risk stratification in multiple myeloma. *Leukemia*, **2014**, 28, 269-77	10.7	387
548	AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia. *British Journal of Haematology*, **2014**, 164, 352-365	4.5	24
547	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. *American Journal of Hematology*, **2014**, 89, 302-5	7.1	2
546	Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. *Clinical Transplantation*, **2014**, 28, 1084-91	3.8	15
545	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. *American Journal of Hematology*, **2014**, 89, 1051-4	7.1	25
544	Accuracy of self-reported tobacco use status among hematopoietic SCT patients. *Bone Marrow Transplantation*, **2014**, 49, 961-5	4.4	3
543	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. *Heart*, **2014**, 100, 383-8	5.1	52
542	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). *Blood*, **2014**, 124, 304-304	2.2	24
541	POEMS Syndrome (Takatsuki Syndrome) **2014**, 179-193		
540	Multiple Myeloma and Related Disorders **2014**, 1991-2017.e7		1
539	Cutaneous manifestations in patients with POEMS syndrome. *International Journal of Dermatology*, **2013**, 52, 1349-56	1.7	25
538	Salvage second hematopoietic cell transplantation in myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 760-6	4.7	87
537	Smoldering multiple myeloma requiring treatment: time for a new definition?. *Blood*, **2013**, 122, 4172-81	12.2	51
536	Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. *Leukemia*, **2013**, 27, 208-12	10.7	78
535	Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. *Cancer*, **2013**, 119, 4308-15	6.4	12
534	Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. *Blood Cancer Journal*, **2013**, 3, e143	7	69
533	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. *American Journal of Hematology*, **2013**, 88, 375-8	7.1	28
532	A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. *Leukemia and Lymphoma* , **2013**, 54, 1713-8	1.9	1

531	Relationship between monoclonal gammopathy and cardiac amyloid type. *Cardiovascular Pathology* , **2013**, 22, 189-94	3.8	47
530	Chronic myopathy due to immunoglobulin light chain amyloidosis. *Molecular Genetics and Metabolism*, **2013**, 108, 249-54	3.7	8
529	Left ventricular device implantation for advanced cardiac amyloidosis. *Journal of Heart and Lung Transplantation*, **2013**, 32, 563-8	5.8	56
528	Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 87-93	4.7	66
527	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. *Mayo Clinic Proceedings*, **2013**, 88, 360-76	6.4	341
526	Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1395-8	4.7	6
525	Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstrm macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 184-6	2	9
524	Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1233-7	4.7	24
523	Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1615-24	4.7	85
522	Immunoglobulins and Laboratory Recognition of Monoclonal Proteins **2013**, 565-588		1
521	Second auto-SCT for treatment of relapsed multiple myeloma. *Bone Marrow Transplantation*, **2013**, 48, 568-73	4.4	47
520	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. *Bone Marrow Transplantation*, **2013**, 48, 1302-7	4.4	58
519	Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. *American Journal of Hematology*, **2013**, 88, 577-80	7.1	18
518	Genotype, echocardiography, and survival in familial transthyretin amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2013**, 20, 263-8	2.7	22
517	A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. *Haematologica*, **2013**, 98, 988-92	6.6	39
516	The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. *Kidney International*, **2013**, 83, 463-70	9.9	86
515	Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT. *Bone Marrow Transplantation*, **2013**, 48, 1543-7	4.4	24
514	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. *Leukemia*, **2013**, 27, 1738-44	10.7	152

513	Thermal stability threshold for amyloid formation in light chain amyloidosis. *International Journal of Molecular Sciences*, **2013**, 14, 22604-17	6.3	22
512	Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *Journal of Clinical Oncology*, **2013**, 31, 4319-24	2.2	146
511	Reply to S. Girnius et al. *Journal of Clinical Oncology*, **2013**, 31, 2750-1	2.2	1
510	Clinical reasoning: a 40-year-old man with CIDP-like illness resistant to treatment. *Neurology*, **2013**, 81, e65-70	6.5	2
509	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. *Bone Marrow Transplantation*, **2013**, 48, 557-61	4.4	124
508	Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. *Journal of Clinical Oncology*, **2013**, 31, 4529-35	2.2	122
507	Implantable cardioverter defibrillators in patients with cardiac amyloidosis. *Journal of Cardiovascular Electrophysiology*, **2013**, 24, 793-8	2.7	118
506	Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients. *Leukemia*, **2013**, 27, 1391-3	10.7	35
505	A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. *Leukemia*, **2013**, 27, 220-5	10.7	70
504	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. *Leukemia*, **2013**, 27, 2062-6	10.7	26
503	Molecular analysis of immunoglobulin genes reveals frequent clonal relatedness in double monoclonal gammopathies. *Blood Cancer Journal*, **2013**, 3, e112	7	10
502	Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. *Gene Therapy*, **2013**, 20, 255-61	4	73
501	Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. *Leukemia*, **2013**, 27, 941-6	10.7	158
500	High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. *Leukemia*, **2013**, 27, 680-5	10.7	113
499	Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. *Blood*, **2013**, 121, 3147-52	2.2	40
498	Outcomes of patients with POEMS syndrome treated initially with radiation. *Blood*, **2013**, 122, 68-73	2.2	54
497	Implications of continued response after autologous stem cell transplantation for multiple myeloma. *Blood*, **2013**, 122, 1746-9	2.2	18
496	How I treat monoclonal gammopathy of renal significance (MGRS). *Blood*, **2013**, 122, 3583-90	2.2	197

495	Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases. *Blood*, **2013**, 122, 1900-1900	2.2	8
494	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT). *Blood*, **2013**, 122, 2-2	2.2	28
493	Survival Outcomes Of Very Young (. *Blood*, **2013**, 122, 2136-2136	2.2	1
492	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. *Blood*, **2013**, 122, 3095-3095	2.2	1
491	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. *Blood*, **2013**, 122, 3117-3117	2.2	2
490	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. *Blood*, **2013**, 122, 3119-3119	2.2	3
489	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. *Blood*, **2013**, 122, 3210-3210	2.2	2
488	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. *Blood*, **2013**, 122, 407-407	2.2	10
487	Monoclonal gammopathies **2013**, 975-986		1
486	Development Of Solid Malignancies In Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS): A Population-Based Study Of 17,315 Patients. *Blood*, **2013**, 122, 3134-3134	2.2	
485	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. *Blood*, **2013**, 122, 2151-2151	2.2	
484	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. *Blood*, **2013**, 122, 1979-1979	2.2	
483	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. *Blood*, **2013**, 122, 3209-3209	2.2	
482	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. *Blood*, **2013**, 122, 754-754	2.2	
481	Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs. *Blood*, **2013**, 122, 1928-1928	2.2	
480	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. *Blood*, **2013**, 122, 1842-1842	2.2	
479	Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis. *Blood*, **2013**, 122, 3142-3142	2.2	
478	Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. *American Journal of Kidney Diseases*, **2012**, 59, 786-94	7.4	137

477	Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS. *European Journal of Haematology*, **2012**, 88, 549-50	3.8	24
476	Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. *European Journal of Haematology*, **2012**, 89, 228-35	3.8	11
475	Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. *British Journal of Haematology*, **2012**, 157, 472-5	4.5	7
474	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. *Cancer*, **2012**, 118, 1585-92	6.4	92
473	Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. *American Journal of Hematology*, **2012**, 87, 1-4	7.1	13
472	Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. *American Journal of Hematology*, **2012**, 87, 51-4	7.1	16
471	Immunoglobulin D amyloidosis: a distinct entity. *Blood*, **2012**, 119, 44-8	2.2	12
470	High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. *Blood*, **2012**, 119, 1117-22	2.2	63
469	Progression in smoldering Waldenstrom macroglobulinemia: long-term results. *Blood*, **2012**, 119, 4462-6	2.2	83
468	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. *Blood*, **2012**, 119, 4860-7	2.2	108
467	How I treat POEMS syndrome. *Blood*, **2012**, 119, 5650-8	2.2	86
466	Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. *Blood*, **2012**, 120, 56-62	2.2	105
465	Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation. *American Journal of Nephrology*, **2012**, 35, 365-71	4.6	26
464	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. *Blood*, **2012**, 119, 2100-5	2.2	181
463	New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *Journal of Clinical Oncology*, **2012**, 30, 4541-9	2.2	553
462	Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 480-6	5.5	101
461	Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. *American Journal of Hematology*, **2012**, 87, E131-2	7.1	24
460	A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. *Muscle and Nerve*, **2012**, 46, 970-7	3.4	18

459	Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. *Mayo Clinic Proceedings*, **2012**, 87, 517-23	6.4	73
458	What do I need to know about immunoglobulin light chain (AL) amyloidosis?. *Blood Reviews*, **2012**, 26, 137-54	11.1	92
457	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580
456	Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. *The Cochrane Library*, **2012**, CD006828	5.2	32
455	Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. *Mayo Clinic Proceedings*, **2012**, 87, 1071-9	6.4	71
454	Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. *Leukemia*, **2012**, 26, 839-41	10.7	10
453	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. *Blood*, **2012**, 120, 4292-5	2.2	362
452	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. *Leukemia*, **2012**, 26, 2317-25	10.7	247
451	Trends and outcomes of modern staging of solitary plasmacytoma of bone. *American Journal of Hematology*, **2012**, 87, 647-51	7.1	49
450	POEMS syndrome: update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2012**, 87, 804-14	7.1	54
449	The clinical spectrum of Castleman's disease. *American Journal of Hematology*, **2012**, 87, 997-1002	7.1	141
448	Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. *Cancer*, **2012**, 118, 6105-9	6.4	52
447	Clonal competition with alternating dominance in multiple myeloma. *Blood*, **2012**, 120, 1067-76	2.2	473
446	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. *British Journal of Haematology*, **2012**, 156, 324-33	4.5	45
445	Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *Journal of Clinical Oncology*, **2012**, 30, 989-95	2.2	582
444	Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. *Nephrology Dialysis Transplantation*, **2012**, 27, 1097-101	4.3	47
443	Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. *Leukemia and Lymphoma*, **2012**, 53, 1057-61	1.9	11
442	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. *Bone Marrow Transplantation*, **2012**, 47, 831-7	4.4	28

441	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. *Leukemia*, **2012**, 26, 1091-7	10.7	67
440	Laboratory persistence and clinical progression of small monoclonal abnormalities. *American Journal of Clinical Pathology*, **2012**, 138, 609-13	1.9	28
439	Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. *Leukemia*, **2012**, 26, 1119-22	10.7	12
438	Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. *Leukemia*, **2012**, 26, 2286-96	10.7	24
437	Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. *Cancer Gene Therapy*, **2012**, 19, 202-11	5.4	25
436	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. *Blood*, **2012**, 119, 5397-404	2.2	125
435	Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1964-8	6.9	56
434	Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. *European Heart Journal Cardiovascular Imaging*, **2012**, 13, 680-9	4.1	72
433	Attenuated oncolytic measles virus strains as cancer therapeutics. *Current Pharmaceutical Biotechnology*, **2012**, 13, 1732-41	2.6	45
432	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. *Blood*, **2012**, 120, 1858-1858	2.2	1
431	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. *Blood*, **2012**, 120, 201-201	2.2	15
430	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. *Blood*, **2012**, 120, 3138-3138	2.2	20
429	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. *Blood*, **2012**, 120, 3972-3972	2.2	6
428	Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis. *Blood*, **2012**, 120, 3992-3992	2.2	1
427	Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. *Blood*, **2012**, 120, 591-591	2.2	1
426	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). *Blood*, **2012**, 120, 602-602	2.2	1
425	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. *Blood*, **2012**, 120, 946-946	2.2	1
424	Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing. *Oncotarget*, **2012**, 3, 502-13	3.3	16

423	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. *Blood*, **2012**, 120, 2973-2973	2.2	
422	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. *Blood*, **2012**, 120, 448-448	2.2	
421	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). *Blood*, **2012**, 120, 600-600	2.2	
420	Molecular Interrogation of Biclonal Multiple Myeloma for Clonal Relatedness.. *Blood*, **2012**, 120, 2928-2928	2.2	
419	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. *Blood*, **2012**, 120, 934-934	2.2	
418	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. *Blood*, **2012**, 120, 599-599	2.2	
417	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2012**, 120, 1988-1988	2.2	
416	Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT). *Blood*, **2012**, 120, 4217-4217	2.2	
415	Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and Prognosis. *Blood*, **2012**, 120, 1861-1861	2.2	
414	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. *Blood*, **2012**, 120, 2059-2059	2.2	
413	Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. *Oncology*, **2012**, 26, 152-61	1.8	9
412	The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. *Nature Reviews Nephrology*, **2011**, 8, 43-51	14.9	178
411	Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al). *Journal of the American Society of Echocardiography*, **2011**, 24, 444-54	5.8	16
410	Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. *Mayo Clinic Proceedings*, **2011**, 86, 12-8	6.4	141
409	Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 1129-36	12.7	144
408	IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM). *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 74-6	2	20
407	Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. *Bone Marrow Transplantation*, **2011**, 46, 970-5	4.4	54
406	A Cost Effective Analysis of a Risk-Adapted Algorithm for Plerixafor Use in Autologous Peripheral Blood Stem Cell Mobilization. *Biology of Blood and Marrow Transplantation*, **2011**, 17, S159-S160	4.7	5

405	Ocular findings in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. *Ophthalmology*, **2011**, 118, 778-82	7.3	64
404	Is there a future for auto-allo HSCT in multiple myeloma?. *Lancet Oncology, The*, **2011**, 12, 1176-7	21.7	3
403	The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. *Canadian Journal of Neurological Sciences*, **2011**, 38, 289-95	1	42
402	Ushering in a new era for POEMS. *Blood*, **2011**, 117, 6405-6	2.2	14
401	Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. *Blood*, **2011**, 117, 6438-44	2.2	77
400	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. *Blood*, **2011**, 118, 1979-88	2.2	69
399	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood*, **2011**, 118, 2970-5	2.2	170
398	Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. *Blood*, **2011**, 118, 1763-5	2.2	53
397	The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. *Blood*, **2011**, 118, 4663-5	2.2	133
396	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. *Leukemia*, **2011**, 25, 689-96	10.7	94
395	Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. *Leukemia*, **2011**, 25, 906-8	10.7	131
394	Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. *Leukemia*, **2011**, 25, 1195-7	10.7	7
393	Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. *Leukemia*, **2011**, 25, 1344-53	10.7	48
392	SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. *Bone Marrow Transplantation*, **2011**, 46, 956-61	4.4	12
391	A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis. *Journal of Clinical Immunology*, **2011**, 31, 1029-37	5.7	1
390	Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. *Annals of Hematology*, **2011**, 90, 101-6	3	32
389	Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. *American Journal of Hematology*, **2011**, 86, 251-5	7.1	74
388	High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa. *American Journal of Hematology*, **2011**, 86, 554-8	7.1	6

387	POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2011**, 86, 591-601	7.1	95
386	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. *American Journal of Hematology*, **2011**, 86, 640-5	7.1	51
385	The definition of IgM multiple myeloma. *American Journal of Hematology*, **2011**, 86, 718-719	7.1	1
384	Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. *Blood*, **2011**, 118, 2985-7	2.2	27
383	Imaging evidence for renomegaly in patients with POEMS syndrome. *Academic Radiology*, **2011**, 18, 1241-43	4.3	1
382	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. *Nephrology Dialysis Transplantation*, **2011**, 26, 2032-6	4.3	72
381	Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. *Bone Marrow Transplantation*, **2011**, 46, 291-3	4.4	5
380	Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 137-8	2.7	4
379	Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. *Clinical Chemistry*, **2011**, 57, 1687-92	5.5	58
378	Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias. *Expert Review of Clinical Immunology*, **2011**, 7, 65-73	5.1	5
377	Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. *Bone Marrow Transplantation*, **2011**, 46, 943-9	4.4	50
376	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. *Blood*, **2011**, 118, 2887-2887	2.2	1
375	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. *Blood*, **2011**, 118, 2942-2942	2.2	2
374	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). *Blood*, **2011**, 118, 3095-3095	2.2	1
373	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. *Blood*, **2011**, 118, 3963-3963	2.2	4
372	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. *Blood*, **2011**, 118, 3981-3981	2.2	1
371	Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). *Blood*, **2011**, 118, 504-504	2.2	3
370	Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. *Blood*, **2011**, 118, 806-806	2.2	1

369	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. *Blood*, **2011**, 118, 2945-2945	2.2	
368	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. *Blood*, **2011**, 118, 4120-4120	2.2	
367	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. *Blood*, **2011**, 118, 3101-3101	2.2	
366	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. *Blood*, **2011**, 118, 2992-2992	2.2	
365	The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis. *Blood*, **2011**, 118, 2868-2868	2.2	
364	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. *Blood*, **2011**, 118, 636-636	2.2	
363	CD147 Is a Novel Regulator of Progression and Proliferation of Multiple Myeloma Plasma Cells. *Blood*, **2011**, 118, 470-470	2.2	
362	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. *Blood*, **2011**, 118, 2682-2682	2.2	
361	Treatment Patterns and Outcomes in Elderly Patients with Multiple Myeloma,. *Blood*, **2011**, 118, 3980-3980	2.2	
360	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. *British Journal of Haematology*, **2010**, 148, 853-8	4.5	2
359	Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. *Leukemia*, **2010**, 24, 1498-505	10.7	30
358	Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. *Leukemia*, **2010**, 24, 1406-11	10.7	38
357	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). *Leukemia*, **2010**, 24, 1934-9	10.7	166
356	Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. *Bone Marrow Transplantation*, **2010**, 45, 490-7	4.4	5
355	Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. *Journal of Clinical Oncology*, **2010**, 28, 1408-14	2.2	114
354	Specificity of serum and urine protein electrophoresis for the diagnosis of monoclonal gammopathies. *Clinical Chemistry*, **2010**, 56, 1899-900	5.5	14
353	Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 2180-7	6.9	95
352	Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. *Neurology*, **2010**, 74, 913-8	6.5	25

351	Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. *European Heart Journal*, **2010**, 31, 1538	9.5	22
350	Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. *Journal of the American Society of Echocardiography*, **2010**, 23, 643-52	5.8	81
349	Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. *Mayo Clinic Proceedings*, **2010**, 85, 232-8	6.4	49
348	Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. *Mayo Clinic Proceedings*, **2010**, 85, 532-7	6.4	52
347	Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. *Neoplasia*, **2010**, 12, 980-92	6.4	26
346	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. *Mayo Clinic Proceedings*, **2010**, 85, 197-9; author reply 201-4	6.4	2
345	Amyloidosis and POEMS syndrome. *Expert Opinion on Pharmacotherapy*, **2010**, 11, 1501-14	4	5
344	Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. *Leukemia and Lymphoma*, **2010**, 51, 2181-7	1.9	92
343	Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. *JACC: Cardiovascular Imaging*, **2010**, 3, 155-64	8.4	333
342	High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 138-40; author reply 140-1	4.7	28
341	A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization. *Biology of Blood and Marrow Transplantation*, **2010**, 16, S197-S198	4.7	10
340	Diagnosis and management of Waldenstrm macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. *Mayo Clinic Proceedings*, **2010**, 85, 824-33	6.4	119
339	Free light-chains and renal disorders: when small is worse Authors' reply. *Lancet, The*, **2010**, 376, 1221-1222	40	2
338	Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. *Clinical Lymphoma, Myeloma and Leukemia* , **2010**, 10, 458-63	2	22
337	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet, The*, **2010**, 375, 1721-8	40	249
336	Recurrent membranoproliferative glomerulonephritis after kidney transplantation. *Kidney International*, **2010**, 77, 721-8	9.9	106
335	Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. *Blood*, **2010**, 115, 2348-53; quiz 2560	2.2	37
334	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. *Blood*, **2010**, 115, 1343-50	2.2	103

333	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. *Blood*, **2010**, 116, 1056-9	2.2	101
332	Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. *Blood*, **2010**, 116, 2019-25; quiz 2197	2.2	46
331	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. *Blood*, **2010**, 116, 5126-9	2.2	125
330	Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. *European Journal of Haematology*, **2010**, 85, 200-8	3.8	8
329	Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. *Cancer*, **2010**, 116, 640-6	6.4	2
328	A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. *American Journal of Hematology*, **2010**, 85, 409-13	7.1	13
327	Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. *American Journal of Hematology*, **2010**, 85, 431-4	7.1	31
326	Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. *American Journal of Hematology*, **2010**, 85, 664-9	7.1	46
325	Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. *American Journal of Hematology*, **2010**, 85, 737-40	7.1	17
324	Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. *American Journal of Hematology*, **2010**, 85, 757-9	7.1	96
323	IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. *American Journal of Hematology*, **2010**, 85, 853-5	7.1	62
322	Current Therapies for Light-Chain Amyloidosis **2010**, 775-793		
321	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. *Blood*, **2010**, 116, 1364-1364	2.2	15
320	Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score. *Blood*, **2010**, 116, 1892-1892	2.2	1
319	Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. *Blood*, **2010**, 116, 1893-1893	2.2	1
318	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. *Blood*, **2010**, 116, 1964-1964	2.2	5
317	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). *Blood*, **2010**, 116, 3053-3053	2.2	1
316	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicitng Outcome In Over 400 Patients. *Blood*, **2010**, 116, 3557-3557	2.2	1

315	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. *Blood*, **2010**, 116, 370-370	2.2	4
314	Non-Clonal Serum Immunoglobulin Free Light Chains (FLC) as Markers of Overall Survival. *Blood*, **2010**, 116, 3893-3893	2.2	2
313	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. *Blood*, **2010**, 116, 863-863	2.2	1
312	Assessing Response and Prognosis in AL Amyloidosis **2010**, 77-93		
311	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. *Blood*, **2010**, 116, 1965-1965	2.2	
310	Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease. *Blood*, **2010**, 116, 3047-3047	2.2	
309	Role of Hepcidin In Anemia of Waldenstro m Macroglobulinemia. *Blood*, **2010**, 116, 4984-4984	2.2	
308	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. *Blood*, **2010**, 116, 4518-4518	2.2	
307	Proteomic Analysis of Immunoglobulin Light Chains (LC) In AL Amyloidosis Shows That the Sequence of Clonal LC Secreted by the Neoplastic Plasma Cells Is Identical to the LC Deposited In the Amyloid Plaques. *Blood*, **2010**, 116, 1909-1909	2.2	
306	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. *Blood*, **2010**, 116, 2253-2253	2.2	
305	Unraveling Early Mortality In Patients with AL Amyloidosis. *Blood*, **2010**, 116, 4990-4990	2.2	
304	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. *Blood*, **2010**, 116, 2970-2970	2.2	1
303	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. *Blood*, **2010**, 116, 987-987	2.2	1
302	Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. *Blood*, **2010**, 116, 3468-3468	2.2	
301	Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. *Blood*, **2010**, 116, 1958-1958	2.2	
300	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. *Blood*, **2010**, 116, 3554-3554	2.2	
299	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. *Blood*, **2010**, 116, 3469-3469	2.2	
298	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. *Blood*, **2010**, 116, 3572-3572	2.2	

297	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood*, **2009**, 113, 5412-7	2.2	714
296	Screening panels for detection of monoclonal gammopathies. *Clinical Chemistry*, **2009**, 55, 1517-22	5.5	213
295	Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. *Kidney International*, **2009**, 75, 420-7	9.9	53
294	Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics. *Neurology*, **2009**, 73, 1308-12	6.5	74
293	Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. *Nephrology Dialysis Transplantation*, **2009**, 24, 3132-7	4.3	85
292	Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. *Journal of Clinical Oncology*, **2009**, 27, 5008-14	2.2	252
291	Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. *American Journal of Hematology*, **2009**, 84, 401-7	7.1	46
290	Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. *American Journal of Hematology*, **2009**, 84, 799-802	7.1	71
289	Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. *British Journal of Haematology*, **2009**, 144, 705-15	4.5	28
288	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*, **2009**, 23, 215-24	10.7	559
287	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. *Leukemia*, **2009**, 23, 1716-30	10.7	123
286	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). *Leukemia*, **2009**, 23, 1904-12	10.7	170
285	Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. *Bone Marrow Transplantation*, **2009**, 43, 619-25	4.4	95
284	IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2009**, 9, 17-8		40
283	Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis. *Journal of the American Society of Echocardiography*, **2009**, 22, 290-8	5.8	31
282	Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma. *Leukemia and Lymphoma*, **2009**, 50, 1033-5	1.9	
281	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *Leukemia and Lymphoma*, **2009**, 50, 781-7	1.9	5
280	Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma. *Clinical Lymphoma and Myeloma*, **2009**, 9, S46-S47		1

279	Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients. *Mayo Clinic Proceedings*, **2009**, 84, 685-693	6.4	136
278	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. *Mayo Clinic Proceedings*, **2009**, 84, 1095-110	6.4	199
277	Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. *Mayo Clinic Proceedings*, **2009**, 84, 114-22	6.4	211
276	Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. *Blood*, **2009**, 114, 4928-32	2.2	63
275	Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. *Blood*, **2009**, 114, 785-90	2.2	101
274	The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. *Blood*, **2009**, 114, 2617-8	2.2	35
273	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood*, **2009**, 114, 518-21	2.2	118
272	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. *Haematologica*, **2009**, 94, 380-6	6.6	80
271	'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis. *Heart*, **2009**, 95, 234-40	5.1	20
270	Depth of Response with Stem Cell Transplantation and Outcome for Multiple Myeloma in the Era of Novel Agents.. *Blood*, **2009**, 114, 1228-1228	2.2	1
269	A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement.. *Blood*, **2009**, 114, 2797-2797	2.2	3
268	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. *Blood*, **2009**, 114, 2868-2868	2.2	3
267	A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis.. *Blood*, **2009**, 114, 3853-3853	2.2	6
266	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. *Blood*, **2009**, 114, 956-956	2.2	1
265	Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. *PLoS ONE*, **2009**, 4, e5169	3.7	58
264	Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. *Current Opinion in Molecular Therapeutics*, **2009**, 11, 43-53		72
263	Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. *Mayo Clinic Proceedings*, **2009**, 84, 685-93	6.4	66
262	Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. *Journal of Clinical Oncology*, **2009**, 27, 7039-7039	2.2	

261	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. *Blood*, **2009**, 114, 2877-2877	2.2	
260	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. *Blood*, **2009**, 114, 3884-3884	2.2	
259	Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. *Leukemia*, **2008**, 22, 1933-7	10.7	120
258	Genetic aberrations and survival in plasma cell leukemia. *Leukemia*, **2008**, 22, 1044-52	10.7	236
257	Impact of additional cytoreduction following autologous SCT in multiple myeloma. *Bone Marrow Transplantation*, **2008**, 42, 259-64	4.4	9
256	Impact of early relapse after auto-SCT for multiple myeloma. *Bone Marrow Transplantation*, **2008**, 42, 413-20	4.4	68
255	Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. *Bone Marrow Transplantation*, **2008**, 41, 1013-9	4.4	17
254	Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. *British Journal of Haematology*, **2008**, 141, 205-11	4.5	17
253	Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. *British Journal of Haematology*, **2008**, 141, 792-8	4.5	58
252	Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. *American Journal of Cardiology*, **2008**, 101, 1039-45	3	93
251	Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. *European Journal of Haematology*, **2008**, 80, 397-406	3.8	104
250	Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. *Mayo Clinic Proceedings*, **2008**, 83, 1131-8	6.4	83
249	Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. *Journal of Heart and Lung Transplantation*, **2008**, 27, 823-9	5.8	96
248	Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). *Biology of Blood and Marrow Transplantation*, **2008**, 14, 6-11	4.7	19
247	Serum uric acid: novel prognostic factor in primary systemic amyloidosis. *Mayo Clinic Proceedings*, **2008**, 83, 297-303	6.4	32
246	Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. *Kidney International*, **2008**, 73, 1282-8	9.9	140
245	Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 335-41	5.9	15
244	Improved survival in multiple myeloma and the impact of novel therapies. *Blood*, **2008**, 111, 2516-20	2.2	1753

243	Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. *Leukemia and Lymphoma*, **2008**, 49, 1724-30	1.9	17
242	Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 666-73	4	13
241	Vertebroplasty in multiple myeloma: outcomes in a large patient series. *American Journal of Neuroradiology*, **2008**, 29, 642-8	4.4	105
240	Screening algorithms for monoclonal gammopathies. *Clinical Chemistry*, **2008**, 54, 1753-5	5.5	10
239	Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. *Leukemia and Lymphoma*, **2008**, 49, 36-41	1.9	68
238	Long-term outcome of autologous stem cell transplantation in light chain deposition disease. *Nephrology Dialysis Transplantation*, **2008**, 23, 2052-7	4.3	74
237	Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. *Cochrane Database of Systematic Reviews*, **2008**, CD006828		15
236	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. *Blood*, **2008**, 111, 785-9	2.2	293
235	Is early, deep free light chain response really an adverse prognostic factor?. *Blood*, **2008**, 111, 2490-1; author reply 2491	2.2	5
234	Appraisal of immunoglobulin free light chain as a marker of response. *Blood*, **2008**, 111, 4908-15	2.2	108
233	Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. *Blood*, **2008**, 112, 1931-41	2.2	54
232	Biology, treatment, and time. *Blood*, **2008**, 112, 2999-3000	2.2	3
231	Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients. *Chest*, **2008**, 133, 969-74	5.3	76
230	Monoclonal gammopathies **2008**, 1167-1180		1
229	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. *American Journal of Hematology*, **2008**, 83, 614-7	7.1	110
228	A novel report of cig-FISH and cytogenetics in POEMS syndrome. *American Journal of Hematology*, **2008**, 83, 840-1	7.1	12
227	High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *New England Journal of Medicine*, **2008**, 358, 91; author reply 92-3	59.2	35
226	Normalization of the Serum Free Light Chain (FLC) Ratio Is Associated with Superior Overall Survival among Myeloma Patients Achieving Immunofixation Negative State: Results Support Incorporation of Serum FLC Ratio in Stringent CR Definition.. *Blood*, **2008**, 112, 1692-1692	2.2	5

225	Immunoglobulin Variable Light Chain Restriction, Cytokine Expression and Plasma Cell-Stromal Cell Interactions in POEMS Syndrome Patients. *Blood*, **2008**, 112, 2744-2744	2.2	5
224	Association of translocation t(11;14) with survival in patients with light chain (AL) amyloidosis. *Journal of Clinical Oncology*, **2008**, 26, 8549-8549	2.2	2
223	POEMS Syndrome and Other Atypical Plasma Cell Disorders **2008**, 571-623		
222	Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.. *Blood*, **2008**, 112, 2301-2301	2.2	
221	Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenstrom Macroglobulinemia. *Blood*, **2008**, 112, 2709-2709	2.2	0
220	The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome. *Blood*, **2008**, 112, 5114-5114	2.2	
219	Castleman disease. *Cancer Treatment and Research*, **2008**, 142, 293-330	3.5	32
218	Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. *Journal of the American Society of Echocardiography*, **2007**, 20, 1194-202	5.8	92
217	Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. *Mayo Clinic Proceedings*, **2007**, 82, 1179-84	6.4	133
216	Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. *Mayo Clinic Proceedings*, **2007**, 82, 323-41	6.4	123
215	POEMS syndrome. *Blood Reviews*, **2007**, 21, 285-99	11.1	293
214	Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. *Bone Marrow Transplantation*, **2007**, 39, 605-11	4.4	50
213	Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). *Bone Marrow Transplantation*, **2007**, 40, 989-93	4.4	10
212	Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. *Clinical Pharmacology and Therapeutics*, **2007**, 82, 700-10	6.1	101
211	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. *Leukemia*, **2007**, 21, 529-34	10.7	168
210	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia*, **2007**, 21, 2035-42	10.7	270
209	6q deletion in Waldenstrm macroglobulinemia is associated with features of adverse prognosis. *British Journal of Haematology*, **2007**, 136, 80-6	4.5	85
208	In vivo and in silico studies on single versus multiple transplants for multiple myeloma. *Cancer Science*, **2007**, 98, 734-9	6.9	6

207	Serum M-spike and transplant outcome in patients with multiple myeloma. *Cancer Science*, **2007**, 98, 1035-40	6.9	12
206	Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell*, **2007**, 12, 131-44	24.3	832
205	Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation. *Annals of Hematology*, **2007**, 86, 303-6	3	17
204	Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis. *Journal of Clinical Immunology*, **2007**, 27, 69-87	5.7	17
203	Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. *Cancer Research*, **2007**, 67, 2982-9	10.1	192
202	Primary systemic amyloidosis with ischemic stroke as a presenting complication. *Neurology*, **2007**, 69, 1136-41	6.5	28
201	Relationship between depth of response and outcome in multiple myeloma. *Journal of Clinical Oncology*, **2007**, 25, 4933-7	2.2	38
200	Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. *Clinical Cancer Research*, **2007**, 13, 6162-7	12.9	58
199	Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 440-4	6.9	32
198	Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome **2007**,		1
197	Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. *Blood*, **2007**, 109, 1228-32	2.2	67
196	The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. *Blood*, **2007**, 109, 465-70	2.2	228
195	Lenalidomide therapy in a patient with POEMS syndrome. *Blood*, **2007**, 110, 1075-6	2.2	82
194	Transplantation for amyloidosis. *Current Opinion in Oncology*, **2007**, 19, 136-41	4.2	72
193	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. *Mayo Clinic Proceedings*, **2007**, 82, 323-341	6.4	119
192	Vascular abnormalities in primary amyloidosis. *European Heart Journal*, **2007**, 28, 1019-24	9.5	40
191	Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. *Haematologica*, **2007**, 92, 1415-8	6.6	102
190	Endocrinopathy in POEMS syndrome: the Mayo Clinic experience. *Mayo Clinic Proceedings*, **2007**, 82, 836-42	6.4	74

189	Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. *Mayo Clinic Proceedings*, **2007**, 82, 1468-73	6.4	112
188	Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. *New England Journal of Medicine*, **2007**, 356, 2582-90	59.2	566
187	Complications of myeloma therapy. *Hematology/Oncology Clinics of North America*, **2007**, 21, 1247-73, xi	3.1	3
186	Tumor Associated Macrophages (TAM) in Skeletal Plasmacytomas of Patients with Multiple Myeloma.. *Blood*, **2007**, 110, 114-114	2.2	1
185	Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma.. *Blood*, **2007**, 110, 1487-1487	2.2	1
184	Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma.. *Blood*, **2007**, 110, 190-190	2.2	6
183	Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition.. *Blood*, **2007**, 110, 246-246	2.2	2
182	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. *Blood*, **2007**, 110, 2477-2477	2.2	1
181	Cytogenetic analysis using multiple myeloma targets in POEMS syndrome. *Journal of Clinical Oncology*, **2007**, 25, 8116-8116	2.2	3
180	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. *Mayo Clinic Proceedings*, **2007**, 82, 1468-1473	6.4	99
179	Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.. *Blood*, **2007**, 110, 1181-1181	2.2	
178	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. *Blood*, **2007**, 110, 3608-3608	2.2	
177	Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.. *Blood*, **2007**, 110, 659-659	2.2	
176	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. *Blood*, **2007**, 110, 1492-1492	2.2	
175	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. *Blood*, **2007**, 110, 2995-2995	2.2	
174	Polyclonal Hypergammaglobulinemia in a Randomized Sample of Ghanaian Adult Males.. *Blood*, **2007**, 110, 960-960	2.2	
173	High Bone Turnover and Increased Angiogenesis Cytokines in Patients with POEMS Syndrome.. *Blood*, **2007**, 110, 3525-3525	2.2	
172	Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. *Experimental Hematology*, **2006**, 34, 713-20	3.1	90

171	6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. *Cancer Genetics and Cytogenetics*, **2006**, 169, 150-3		85
170	Quantitative analysis of clonal bone marrow CD19+ B cells: use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis. *Clinical Immunology*, **2006**, 120, 106-20	9	13
169	Natural history and therapy of 66 patients with mixed cryoglobulinemia. *American Journal of Hematology*, **2006**, 81, 511-8	7.1	53
168	Two-dimensional acoustic pattern derived strain parameters closely correlate with one-dimensional tissue Doppler derived strain measurements. *European Journal of Echocardiography*, **2006**, 7, 315-21		39
167	High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. *Expert Review of Anticancer Therapy*, **2006**, 6, 343-60	3.5	20
166	A phase II trial of imatinib in patients with refractory/relapsed myeloma. *Leukemia and Lymphoma*, **2006**, 47, 39-42	1.9	38
165	Vascular endothelial growth factor and POEMS. *Neurology*, **2006**, 66, 10-2	6.5	131
164	Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. *Journal of Interferon and Cytokine Research*, **2006**, 26, 83-95	3.5	36
163	Autologous stem cell transplantation and IgM amyloidosis. *Leukemia and Lymphoma*, **2006**, 47, 1006-12	1.9	17
162	Natural history of thromboembolism in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2006**, 13, 31-6	2.7	23
161	Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. *Mayo Clinic Proceedings*, **2006**, 81, 693-703	6.4	152
160	Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. *Mayo Clinic Proceedings*, **2006**, 81, 1047-53	6.4	193
159	Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. *Mayo Clinic Proceedings*, **2006**, 81, 1575-8	6.4	152
158	Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. *Clinical Lymphoma and Myeloma*, **2006**, 6, 384-8		73
157	Response to rituximab in patients with type II cryoglobulinemia. *Clinical Lymphoma and Myeloma*, **2006**, 7, 140-4		23
156	Enhancing the therapeutic index of radiation in multiple myeloma. *Drug Discovery Today Disease Mechanisms*, **2006**, 3, 515-522		5
155	Prevalence of monoclonal gammopathy of undetermined significance. *New England Journal of Medicine*, **2006**, 354, 1362-9	59.2	902
154	Primary cardiac amyloidosis with 20-year survival. *Cardiovascular Pathology*, **2006**, 15, 331-5	3.8	5

153	Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. *Archives of Dermatology*, **2006**, 142, 1298-302		66
152	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*, **2006**, 107, 3378-83	2.2	198
151	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. *Blood*, **2006**, 107, 3384-8	2.2	56
150	Clinical implication of centrosome amplification in plasma cell neoplasm. *Blood*, **2006**, 107, 3669-75	2.2	79
149	Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. *Blood*, **2006**, 107, 4063-70	2.2	33
148	Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. *Blood*, **2006**, 108, 2755-63	2.2	147
147	Immunoglobulin free light chains and solitary plasmacytoma of bone. *Blood*, **2006**, 108, 1979-83	2.2	122
146	Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. *British Journal of Haematology*, **2006**, 133, 158-64	4.5	108
145	Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. *Bone Marrow Transplantation*, **2006**, 37, 1003-8	4.4	55
144	Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. *Bone Marrow Transplantation*, **2006**, 37, 1017-22	4.4	46
143	Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. *Leukemia*, **2006**, 20, 807-13	10.7	112
142	Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. *Leukemia*, **2006**, 20, 2034-40	10.7	158
141	Ploidy status rarely changes in myeloma patients at disease progression. *Leukemia Research*, **2006**, 30, 266-71	2.7	26
140	High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels.. *Blood*, **2006**, 108, 3514-3514	2.2	3
139	Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02).. *Blood*, **2006**, 108, 3527-3527	2.2	9
138	Prevalence of Light-Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS) among Olmsted County, Minnesota Residents Aged 50 Years or Greater.. *Blood*, **2006**, 108, 5060-5060	2.2	2
137	Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.. *Blood*, **2006**, 108, 798-798	2.2	23
136	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. *Blood*, **2006**, 108, 3407-3407	2.2	

135	Idiopathic Bence Jones Proteinuria: Clinical Course and Prognosis.. *Blood*, **2006**, 108, 3493-3493	2.2	1
134	Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.. *Blood*, **2006**, 108, 3500-3500	2.2	
133	The Serum M-Spike and Transplant Outcome in Patients with Multiple Myeloma.. *Blood*, **2006**, 108, 5441-5441	2.2	
132	Extent of Hematologic Response Is Important in Determining Outcome in Transplanted Patients with Primary Amyloidosis AL. Importance of Achieving CR.. *Blood*, **2006**, 108, 611-611	2.2	
131	Elimination of the Need for Urine Studies during Diagnostic Studies of Monoclonal Gammopathies by the Combined Use of Serum Immunofixation and Serum Free Light Chain Assays.. *Blood*, **2006**, 108, 5011-5011	2.2	
130	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. *Blood*, **2006**, 108, 3587-3587	2.2	
129	Sequential Heart and Autologous Stem Cell Transplantation for AL Amyloidosis.. *Blood*, **2006**, 108, 3092-3092	2.2	
128	Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. *European Heart Journal*, **2005**, 26, 173-9	9.5	73
127	Treatment options for POEMS syndrome. *Expert Opinion on Pharmacotherapy*, **2005**, 6, 945-53	4	18
126	The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. *Leukemia and Lymphoma*, **2005**, 46, 1287-94	1.9	19
125	Amyloidosis: diagnosis and management. *Clinical Lymphoma and Myeloma*, **2005**, 6, 208-19		47
124	Multiple myeloma: clinical features and indications for therapy. *Best Practice and Research in Clinical Haematology*, **2005**, 18, 553-68	4.2	47
123	Neurological aspects of multiple myeloma and related disorders. *Best Practice and Research in Clinical Haematology*, **2005**, 18, 673-88	4.2	102
122	Amyloidosis. *Best Practice and Research in Clinical Haematology*, **2005**, 18, 709-27	4.2	63
121	Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. *Blood*, **2005**, 106, 812-7	2.2	452
120	Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. *Blood*, **2005**, 105, 794-803	2.2	51
119	A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. *Blood*, **2005**, 106, 2156-61	2.2	106
118	Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. *Blood*, **2005**, 106, 3353-7	2.2	36

117	Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. *Blood*, **2005**, 106, 2837-40	2.2	285
116	Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. *Blood*, **2005**, 106, 2276-9	2.2	178
115	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. *Blood*, **2005**, 106, 4050-3	2.2	541
114	Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. *Archives of Dermatology*, **2005**, 141, 1277-82		46
113	Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. *Kidney International*, **2005**, 68, 1464-71	9.9	10
112	A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. *Leukemia*, **2005**, 19, 118-25	10.7	39
111	PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. *Experimental Hematology*, **2005**, 33, 784-95	3.1	48
110	Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. *American Journal of Kidney Diseases*, **2005**, 45, 102-11	7.4	30
109	Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. *American Journal of Kidney Diseases*, **2005**, 46, 270-7	7.4	59
108	Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. *American Journal of Transplantation*, **2005**, 5, 1660-70	8.7	65
107	Current status of stem cell transplantation for multiple myeloma. *Current Treatment Options in Oncology*, **2005**, 6, 229-40	5.4	1
106	Treatment of Castleman's disease. *Current Treatment Options in Oncology*, **2005**, 6, 255-66	5.4	56
105	Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. *Clinical Chemistry*, **2005**, 51, 878-81	5.5	200
104	Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. *Journal of Clinical Oncology*, **2005**, 23, 5668-74	2.2	93
103	POEMS Syndrome. *Hematology American Society of Hematology Education Program*, **2005**, 2005, 360-7	3.1	62
102	Bortezomib for myeloma -- much ado about something. *New England Journal of Medicine*, **2005**, 352, 2546-8	59.2	18
101	The Role of Stem Cell Mobilization Regimen on Lymphocyte Collection Yield and Survival after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.. *Blood*, **2005**, 106, 1174-1174	2.2	1
100	Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis.. *Blood*, **2005**, 106, 252-252	2.2	2

99	The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.. *Blood*, **2005**, 106, 3396-3396	2.2	5
98	Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.. *Blood*, **2005**, 106, 3475-3475	2.2	5
97	Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone.. *Blood*, **2005**, 106, 5080-5080	2.2	1
96	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. *Blood*, **2005**, 106, 781-781	2.2	3
95	Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System.. *Blood*, **2005**, 106, 1164-1164	2.2	1
94	6q Deletion in Waldenstro m Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival.. *Blood*, **2005**, 106, 986-986	2.2	1
93	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2005**, 106, 5420-5420	2.2	
92	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. *Blood*, **2005**, 106, 3381-3381	2.2	
91	Response to Rituximab in Type II Cryoglobulinemia.. *Blood*, **2005**, 106, 3499-3499	2.2	
90	Role of Second Stem Cell Transplant in Patients with Amyloidosis Who Are Refractory or Relapsing.. *Blood*, **2005**, 106, 5469-5469	2.2	
89	Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years.. *Blood*, **2005**, 106, 1173-1173	2.2	
88	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Transplanted for Multiple Myeloma.. *Blood*, **2005**, 106, 1165-1165	2.2	
87	In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.. *Blood*, **2005**, 106, 2567-2567	2.2	1
86	The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).. *Blood*, **2005**, 106, 1545-1545	2.2	
85	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. *Blood*, **2005**, 106, 5422-5422	2.2	
84	Clinical Outcome of IgM Amyloidosis (AL) Following Stem Cell Transplantation.. *Blood*, **2005**, 106, 5470-5470	2.2	
83	One Half of Patients with Waldenstro m Macroglobulinemia Have Large Deletions of Chromosome 6q.. *Blood*, **2005**, 106, 1546-1546	2.2	
82	POEMS Syndrome (Osteosclerotic Myeloma) **2005**, 2453-2469		3

81	Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. *Clinical Cancer Research*, **2005**, 11, 1210-8	12.9	42
80	Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. *Journal of Clinical Oncology*, **2004**, 22, 3751-7	2.2	593
79	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. *Bone Marrow Transplantation*, **2004**, 34, 161-7	4.4	73
78	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. *Bone Marrow Transplantation*, **2004**, 34, 235-9	4.4	55
77	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. *Bone Marrow Transplantation*, **2004**, 34, 485-90	4.4	48
76	Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. *Bone Marrow Transplantation*, **2004**, 34, 1025-31	4.4	90
75	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. *Leukemia*, **2004**, 18, 624-7	10.7	79
74	The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. *Leukemia*, **2004**, 18, 1085-92	10.7	88
73	Treatment of POEMS syndrome. *Current Treatment Options in Oncology*, **2004**, 5, 249-57	5.4	31
72	Therapy for immunoglobulin light chain amyloidosis: the new and the old. *Blood Reviews*, **2004**, 18, 17-37	11.1	49
71	Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. *Blood*, **2004**, 104, 3400-7	2.2	174
70	Clinical course of patients with relapsed multiple myeloma. *Mayo Clinic Proceedings*, **2004**, 79, 867-74	6.4	266
69	Peripheral blood stem cell transplant (PBSCT) in a large series of patients with poems syndrome. *Biology of Blood and Marrow Transplantation*, **2004**, 10, 14-15	4.7	11
68	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*, **2004**, 104, 1881-7	2.2	266
67	Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. *Blood* , **2004**, 104, 40-2	2.2	110
66	Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. *Blood*, **2004**, 103, 3960-3	2.2	193
65	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma.. *Blood*, **2004**, 104, 2927-2927	2.2	1
64	Combination Therapy with CC-5013 (Lenalidomide; Revlimid) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. *Blood*, **2004**, 104, 331-331	2.2	11

63	Low Dose Single Agent Thalidomide Is Tolerated in Patients with Primary Systemic Amyloidosis, but Responses Are Limited.. *Blood*, **2004**, 104, 4920-4920	2.2	8
62	Performance of Free Light Chain Assays in Clinical Practice.. *Blood*, **2004**, 104, 757-757	2.2	3
61	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. *Blood*, **2004**, 104, 892-892	2.2	1
60	Excessive Weight Gain during Mobilization Increases First Year Mortality Following High Dose Therapy and Stem Cell Transplantation in Patients with Primary Amyloidosis.. *Blood*, **2004**, 104, 937-937	2.2	1
59	Neurologic aspects of monoclonal gammopathy of undetermined significance, multiple myeloma and related disorders **2004**, 350-365		1
58	Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis, AL) **2004**, 157-195		1
57	Neuropathy Associated With Plasma Cell Proliferative Disorders **2004**, 35-51		1
56	Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant **2004**, 121-123		
55	PS-341 Induces Selective Radiosensitization of Multiple Myeloma Cells.. *Blood*, **2004**, 104, 2478-2478	2.2	
54	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis **2004**, 67-69		1
53	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. *Blood*, **2004**, 104, 928-928	2.2	
52	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. *Blood*, **2004**, 104, 1493-1493	2.2	
51	Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells.. *Blood*, **2004**, 104, 2392-2392	2.2	
50	Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide Predict Survival in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant **2004**, 85-87		0
49	Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide Predict Survival in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant **2004**, 85-87		
48	Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma.. *Blood*, **2004**, 104, 2412-2412	2.2	1
47	Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.. *Blood*, **2004**, 104, 4852-4852	2.2	
46	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide **2004**, 67-69		

45	Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2003**, 10, 215-23	2.7	30
44	Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2003**, 10, 257-61	2.7	113
43	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. *Blood*, **2003**, 101, 827-30	2.2	54
42	Prognostic value of angiogenesis in solitary bone plasmacytoma. *Blood*, **2003**, 101, 1715-7	2.2	86
41	The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. *Blood*, **2003**, 102, 2562-7	2.2	230
40	Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. *Blood*, **2003**, 101, 2156-8	2.2	83
39	Acute neuropathies after peripheral blood stem cell and bone marrow transplantation. *Muscle and Nerve*, **2003**, 28, 733-6	3.4	15
38	Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. *Bone Marrow Transplantation*, **2003**, 32, 317-24	4.4	48
37	Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. *Bone Marrow Transplantation*, **2003**, 32, 587-92	4.4	27
36	Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. *Leukemia*, **2003**, 17, 427-36	10.7	186
35	Thalidomide as initial therapy for early-stage myeloma. *Leukemia*, **2003**, 17, 775-9	10.7	200
34	Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. *Mayo Clinic Proceedings*, **2003**, 78, 34-9	6.4	111
33	Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. *Lancet, The*, **2003**, 361, 1787-9	40	229
32	Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clinic Proceedings*, **2003**, 78, 21-33	6.4	1526
31	POEMS syndrome: definitions and long-term outcome. *Blood*, **2003**, 101, 2496-506	2.2	577
30	High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. *Journal of Clinical Oncology*, **2002**, 20, 189-96	2.2	157
29	Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. *Cancer Genetics and Cytogenetics*, **2002**, 132, 55-60		51
28	Immunoglobulin light chain amyloidosis and the kidney. *Kidney International*, **2002**, 61, 1-9	9.9	58

27	Bone marrow angiogenesis in multiple myeloma: effect of therapy. *British Journal of Haematology*, **2002**, 119, 665-71	4.5	42
26	Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. *Journal of Clinical Oncology*, **2002**, 20, 4319-23	2.2	433
25	A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2002**, 9, 24-30	2.7	42
24	Stem cell transplantation for the management of primary systemic amyloidosis. *American Journal of Medicine*, **2002**, 113, 549-55	2.4	135
23	Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. *Clinical Cancer Research*, **2002**, 8, 2210-6	12.9	187
22	Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. *Blood*, **2001**, 98, 579-85	2.2	222
21	Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. *Blood*, **2001**, 98, 2266-8	2.2	111
20	Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. *American Journal of Hematology*, **2001**, 68, 269-75	7.1	50
19	Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. *Bone Marrow Transplantation*, **2001**, 28, 305-9	4.4	57
18	High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. *Bone Marrow Transplantation*, **2001**, 28, 381-5	4.4	36
17	Thalidomide for previously untreated indolent or smoldering multiple myeloma. *Leukemia*, **2001**, 15, 1274-6	10.7	138
16	Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. *American Journal of Cardiology*, **2001**, 88, 813-5	3	30
15	Retrospective cohort study of 148 patients with polyclonal gammopathy. *Mayo Clinic Proceedings*, **2001**, 76, 476-87	6.4	100
14	Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. *Journal of Clinical Oncology*, **2001**, 19, 3350-6	2.2	128
13	Effect of complete response on outcome following autologous stem cell transplantation for myeloma. *Bone Marrow Transplantation*, **2000**, 26, 979-83	4.4	47
12	Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. *Bone Marrow Transplantation*, **2000**, 25, 465-70	4.4	63
11	Symptomatic cryoglobulinemia. *Current Treatment Options in Oncology*, **2000**, 1, 105-18	5.4	21
10	Thalidomide in the treatment of relapsed multiple myeloma. *Mayo Clinic Proceedings*, **2000**, 75, 897-901	6.4	147

9	Prognostic value of bone marrow angiogenesis in multiple myeloma. *Clinical Cancer Research*, **2000**, 6, 3111-6	12.9	219
8	Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. *Leukemia and Lymphoma*, **1999**, 35, 599-605	1.9	26
7	Amyloidosis. *Hematology/Oncology Clinics of North America*, **1999**, 13, 1211-33, ix	3.1	130
6	Cryoglobulinemia. *Hematology/Oncology Clinics of North America*, **1999**, 13, 1315-49	3.1	77
5	Amyloidosis: recognition, confirmation, prognosis, and therapy. *Mayo Clinic Proceedings*, **1999**, 74, 490-4	6.4	35
4	Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy. *Mayo Clinic Proceedings*, **1999**, 74, 490-494	6.4	92
3	POEMS syndrome and paraproteinemic syndromes: management and follow-up225-244		
2	DIAGNOSIS AND TREATMENT OF POEMS SYNDROME182-194		1
1	Amyloidosis and other rare plasma cell dyscrasias184-206		